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Prevalence of onychomycosis, as high as 26.9% in the general population, can be reduced 
by improving current antifungal treatment. This could be accomplished by understanding 
prognostic factors, especially healthy nail growth, associated with achieving complete 
cure. This population-based study aimed to evaluate if healthy nail length or percentage 
of total full nail length as healthy can be early indictors for complete cure. Logistics 
regression analyses were performed by comparing variables between a population who 
achieved the complete cure and a population who failed after both populations received 
the same antifungal treatment in two large randomized double-blinded clinical trials that 
assessed drug efficacy. Results showed that the largest odds ratios for healthy nail length 
(mm) and percent of total nail grown as healthy (%) were achieved at Week 12 with 1.63 
and 1.07, respectively. Mean healthy nail length at Week 12 was 3.56 mm among cured 
patients and 1.90 mm among failed patients. Other significant baseline factors for the 
cure were: younger in age; naïve to antifungal treatment; and having less severe 
disease. Growth of healthy nail during the treatment period is significantly associated 
with achievement of complete cure. Treatment success might be improved by monitoring 
the healthy nail growth. This study bears public health importance and can foster positive 
social changes because better managed disease can improve patient’s quality of life and 
reduce financial burdens to the healthcare system. It could also be a tool for researchers 
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INTRODUCTION TO THE STUDY 
Background of the Study 
Onychomycosis is a fungal infection of the nail unit and occurs worldwide. The 
disease accounts for 30% of all superficial fungal infections and about 50% of all nail 
disorders (Jain & Sehgal, 2000). According to population-based studies, the prevalence of 
onychomycosis in the general population is between 2 to 8%, which may be an 
underestimate due to the low level of diagnosis or underreporting (Haneke & Roseeuw, 
1999). The estimated prevalence in North America is 6.5 to 13% (Gupta, Taborda, et al., 
2000). The prevalence of onychomycosis in Europe is estimated at 26.9% (Haneke & 
Roseeuw).  
Studies (Haneke & Roseeuw, 1999; Jain & Sehgal, 2000) showed an increase in 
onychomycosis in recent decades, probably due to several factors, including an aging 
population, changes in lifestyle such as wearing unfit shoes or participating in sporting 
events, an expanding immunosuppressed population, increased vigilance in detecting the 
disease, increased use of communal locker rooms, and professional hazards.  
Toenails are involved in the majority of onychomycosis cases. The ratio of 
fingernail to toenail onychomycosis was found to be 1:4 in Spain and 1:19 in Canada. 
This may be partly because the toenails grow 50-66% more slowly than the fingernails. It 
takes 12-18 months to grow a big toenail anatomically but only 6 months to replace a 
fingernail. Slow growth may make it easier for the fungus to establish the infection 
(Haneke & Roseeuw, 1999).  
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Onychomycosis affects the lives of individuals with the disease. Once infected, 
the nail corrodes from the inside out and results in onycholysis (i.e., separation of the nail 
from the nail bed) and discoloration. Patients report pain and discomfort (Gupta, 
Taborda, et al., 2000). They often present with a disfigured, especially thickened nail 
plate. The thickening can cause a problem with toenail cutting and requires some patients 
to use padding or special shoes to accommodate the thickened toenails. Distorted nails, 
sometimes with sharp edges, could abrade adjacent skin and cause compensatory changes 
in adjacent hard and soft tissues such as subungual corns, calluses, and ulcers. Patients 
with diabetes or peripheral vascular diseases are particularly at risk of the complications 
of adjacent skin changes because of poor circulation, which will prolong the wound 
healing time and leave the patients vulnerable for developing cellulitis or even 
septicemia. Many patients may also have negative self-images (Gupta, Taborda, et al.; 
Turner & Testa, 2000). Shame may preclude patients from acting in social and 
occupational circumstances where they feel unwilling to show their hands or feet. 
Therefore, even if considering it as a cosmetic problem, this infection is often worth the 
treatment.  
Treatment of onychomycosis is a challenging task because the nail fungus often 
does not live on the nail surface but in the nail bed where there is a rich blood supply, 
which encourages growth. Treatment is also challenging because the nail bed uses the 
nail as a protective shield so that many topical medicines do not reach the affected area. 
In addition, some of the systemic drugs show poor affinity to the nail bed tissues. Even 
with currently available treatments, the rate of complete elimination of the disease is 
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unsatisfactory, with a rate ranging between 20 and 50% (Baran & Kaoukhov, 2005; de 
Berker, 2004). 
The terbinafine oral tablet is considered the gold standard treatment of 
dermatophyte onychomycosis (Crawford et al., 2002; Darkes, Scott, & Goa, 2003; Gupta, 
Ryder, & Johnson, 2004; Loo, 2006; Roberts, Taylor, & Boyle, 2003). The complete 
course of treatment for toenail onychomycosis is a 12-week daily dosing with oral 
terbinafine 250 mg tablets. The product leaflet indicates a 38% complete cure rate 
(Novartis Pharmaceutical Corporation, 2005). The meta-analysis of published data 
indicates a 35% to 50% disease-free nail after a standard course of the treatment (Epstein, 
1998). Both researchers and physicians feel this rate could be improved (Gupta & Ryder, 
2003, Gupta & Tu, 2006). Some researchers have recommended introducing a shorter 
course of oral dose as a booster treatment during the follow-up period, combining oral 
dosing with a topical medicine or debridement procedure (Baran & Kaoukhov, 2005; 
Gupta & Ryder; Gupta & Tu), or increasing the standard treatment duration (Heikkila & 
Stubb, 2002). Other researchers opted to wait 72 weeks longer before repeating the 
antifungal medication (De Cuyper & Hindryckx, 1999; Sigurgeirsson, Olafsson, et al., 
2002). Practice is inconsistent across medical fields and strategies often are in principal 
only, without providing clear guidelines on when and how additional therapies should be 
used. Also, the true benefit of additional medication has not yet been fully reported. 
Therefore, there is a clear benefit for both the research and medical communites to have a 
better and more precise way to predict treatment outcome, including indicators for 
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treatment success, identified in the early stages of treatment as well as for any additional 
booster treatments.  
Problem Statement 
Success of antifungal treatment is assessed by whether or not a patient has 
achieved a complete cure. Complete cure, a dichotomous variable, is defined as 
completely healthy big toenail regrowth (i.e., clinical cure) and negative mycological 
culture and microscopy results (i.e., mycological cure) about 36 weeks after conclusion 
of a standard 12-week daily dosing of systemic treatment. Though total healthy nail 
growth is one of the criteria for a complete cure assessment, the effect of healthy nail 
growth during the treatment and posttreatment period on treatment success has only been 
assessed in a study with 35 patients (Sommer et al., 2003). The results from the study 
were inconclusive due to lack of sufficient power. Therefore, the associations of healthy 
nail growth--alone or in combination with other factors--and achievement of a complete 
cure are still uncertain. These associations will be studied here.  
Purpose of the Study 
This population-based study was aimed at examining the relationship between 
healthy nail growth during the treatment and posttreatment periods and achievement of a 
complete cure. It was intended to identify the best point in time and the best prognostic 
variables for predicting the achievement of a complete cure. It also assessed the effect of 
some baseline factors and mycological results on the treatment outcome.  
 5
 
Nature of the Study 
This is a prospective study with repeated measurements taken from patients 
treated with a standard course of terbinafine oral tablets in two identically designed 
clinical trials conducted by Novartis Pharmaceutical Corporation. The study compared a 
set of factors between patients who achieved complete cure and patients who failed to 
achieve complete cure in an effort to identify significant factors associated with treatment 
success. 
Research Questions and Hypotheses 
Healthy nail growth is a key surrogate marker for the disease’s progression and 
for assessment of treatment outcome. Since healthy nail growth can be measured as 
actual length grown or expressed as a percentage of the total full nail length grown as 
healthy, this population-based study assessed how each variable was associated with a 
successful outcome. Specifically, this study examined hypotheses associated with the 
following two questions. 
Question 1: What is the link between achievement of a complete cure and the 
speed of healthy nail growth as measured by the length of healthy nail during the trial 
period? 
Null Hypothesis: There is no association between the achievement of a complete 




Alternative Hypothesis: There is an association between the achievement of a 
complete cure and the change in the length of healthy nail growth during the 48-week 
period. 
Question 2: What is the association between the achievement of a complete cure 
and the proportion of total nail regrown as healthy over the trial period? 
Null Hypothesis: There is no association between the achievement of a complete 
cure and the change in the percentage of total full nail length grown as healthy at any 
point in time during the 48-week period. 
Alternative Hypothesis: There is an association between the achievement of a 
complete cure and the change in the percentage of total full nail length grown as healthy 
during the 48-week period. 
To test these hypotheses, a determination of whether complete cure was or wasn’t 
achieved was based on mycological results and healthy nail growth status by the Week 48 
assessment, since complete big toenail growth takes up to 12-18 months. Healthy nail 
growth was measured by (a) length (in millimeters) between the nail proximal fold and 
the lowest point of the disease and healthy nail border, and (b) nail growth as a 
percentage of total full nail length. These measurements were taken at Weeks 4, 8, 12, 16, 
24, and 36 after starting treatment. Other factors included age, sex, disease severity 
(measured by percentage of infected nail) prior to starting treatment, antifungal treatment 
history, and clinical signs. The analysis was done to assess if the nail growth pattern 




Failure of antifungal treatment can only be known after a long follow-up period. 
If treatment failure can be predicted earlier, the probability of success can be improved 
by other means (Sommer et al., 2003). However, identifying these prognostic factors has 
been a slow process. Only limited literature has reported the factors associated with 
treatment success. Since healthy nail growth is a reflection of the effectiveness of 
treatment and ability of the nail to grow, monitoring healthy nail growth can be the best 
indicator for treatment success.  
This study used archived data prospectively collected from two large clinical 
trials. It was possible to not only assess the change in healthy nail growth over time, but 
also to compare such changes between patients who achieved a complete cure and those 
who failed at certain points in time. Limiting the study to patients who received the same 
duration of the same drug treatment minimized the impact of underdosing, overdosing, or 
treating with a different drug. Though nail growth can be affected by factors such as age 
and gender, the researcher adjusted for these potential confounders when evaluating the 
association between nail growth and treatment success. Therefore, the study results have 
high validity. 
Though it is especially challenging to monitor nail growth over a long period of 
time in a large sample, this study provides much-needed information to both physicians 
and researchers. 
Definition of Terms 
Definitions for the terms used in this report are provided in this section.  
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Clinical cure: Completely healthy, 0% residual involvement of the target toenail. 
Complete cure: A complete growth of healthy nail and negative microscopy and 
negative culture from nail sample. 
Debridement: A procedure to remove diseased nail using scalpel or nail file.
 Dermatophytes: A term that embraces the imperfect fungi of the genera 
Epidermophyton, Microsporum, and Trichophyton. It causes infections of the skin, hair, 
and nails because of their ability to obtain nutrients from keratinized material in the skin, 
hair, and nail. 
Dermatophytoma: A dense white linear or round area under an onycholytic nail 
plate, which consists of a densely packed clump of often thick-walled dermatophyte 
haphae. 
Eponychium: Also called the cuticle, it is situated between the skin of the finger 
or toe and the nail plate, fusing these structures together and providing a waterproof 
barrier.  
Hyperkeratosis: Hypertrophy of the skin/nail. 
Hyponychium: The area between the nail plate and the fingertip, it is the junction 
between the free edge of the nail and the skin of the fingertip, providing a waterproof 
barrier. 
Lunula: Visible part of the nail matrix; often called half moon. 
KOH test: The nail sample is treated with potassium hydroxide (KOH), and then 




Macroconidia: Two- or more-celled, smooth-, thin- or thick-walled, and cigar 
shaped.  
Microconidia: One-celled and round or pyriform in shape.  
Microscope: See KOH test. 
Mold: Includes all species of microscopic fungi that grow in the form of 
multicellular filaments, called hyphae. Scopulariopsis brevicaulis is a common mold 
cause of onychomycosis. 
Mycological culture: A process to grow fungus on the medium for the 
identification of fungus species.  
Mycological cure: Culture negative for dermatophytes and negative KOH 
microscopy from the nail sample.  
Nail matrix: The area approximately 5 mm beneath the proximal fold, where the 
nail is made. 
Nail plate: A term for the actual nail, the nail plate is made of translucent keratin. 
The pink appearance of the nail comes from the blood vessels underneath the nail. The 
underneath surface of the nail plate has grooves along the length of the nail that help 
anchor it to the nail bed.  
Onycholysis: Separation of the nail from nail bed along the lateral margins 
Onychomycosis: Nail is infected by fungal, mainly dermatophytes such as 
Trichophyton rubrum, Trichophyton mentagrophytes, Epidermatophyton floccosum, and 
so on.  
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Paronychial inflammation: Inflammation due to infection of the skin folds 
surrounding the nail plate. 
Perionychium: The skin that overlays the nail plate on its sides. It is also known 
as the paronychial edge. 
Relapse: Patients with complete cure prior to Week 48 who tested positive again 
by mycological culture or positive KOH microscopy and clinical assessment. 
Ratio of estimated prevalence (REP) = (Onychomycosis per decade of age × total 
population) / (100 × citizen in defined period of age) 
Tinea pedis: Fungal infection of foot skin. 
Assumptions 
The study was conducted under two assumptions. The first assumption was that 
new nail will grow out healthy and evenly push through the nail bed after the fungi that 
cause onychomycosis have been killed. The second assumption was that the change in 
healthy nail length will reflect the time needed to grow a completely healthy new nail. 
The shortest distance between the proximal nail fold and healthy-disease boarder would 
require the longest time to replace the diseased nail and should be a good predictor of the 
final treatment outcome. 
Limitations 
The original clinical trials by Novartis Pharmaceutical Corporation were designed 
to assess the efficacy of continuous dosing of 250 mg terbinafine oral tablets versus 
intermittent dosing of 350 mg terbinafine oral capsules. The trials were completed in 
November 2003. This study was limited to the data collected from these trials.  
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Nail growth at each trial visit was captured by photographing each patient. 
Measurements of healthy nail length at baseline and the end of the trial were available 
from the archived database. The healthy nail length from other points in time needed to 
be measured from the photographs by this researcher. Therefore, the quality of the 
photographs might have affected some assessments and disqualified some patients from 
participation in this study.  
Though infection of the nail matrix and nail thickness have been shown to be 
associated with treatment success, they were not assessed in this study because the data 
were not collected in the original trials. The interaction with healthy nail growth will 
need to be assessed in future studies. 
Significance of the Study 
Because of the disease’s high prevalence, it is important to treat patients 
successfully. However, fungal infections of the nail are very difficult to treat because the 
fungus commonly lives beneath the nail where it is hard for medicine to reach. The 
appearance of infected nails may affect patients’ social life as well as self-confidence 
(Elewski, 2000; Gupta, Taborda, et al.; Turner & Testa, 2000). The patients may be 
embarrassed to wear sandals or open-toed shoes. They may not swim in public. Their 
partners may be impacted by the presence or appearance of the infection, which may 
cause a strain in personal relationships.  
Left untreated, the nails may also cause medical problems. Infected nails could be 
reservoirs that spread the fungus to other body areas (Szepietowski, Reich, Garlowska, 
Kulig, & Baran, 2006), especially when immunity is compromised. For patients with 
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diabetes or peripheral vascular disease, untreated onychomycosis may decrease their 
mobility (Jones, 2003). Therefore, prompt treatment is required. However, the current 
success rate is not optimal and treatment outcome is only known after a long waiting 
period. This causes both medical and emotional burdens for the patients. If treatment 
outcome could be predicted at an early stage of the treatment, physicians could be guided 
to provide appropriate adjuvant treatment to boost the treatment success rate. This may 
increase patient treatment compliance. It could also reduce financial as well as emotional 
burdens by avoiding unnecessary second full courses of treatment and by shortening the 
waiting period for results. Therefore, it can improve the quality of life for sufferers.  
If treatment outcome could be predicted at an early stage of the treatment, it could 
also help researchers to filter out better antifungal candidate compounds for further 
development. DiMasi, Hansen, and Grabowski (2003) reported that current drug 
development processes take an average 90.3 months and $802 million to move a drug 
from the start of the first clinical trial to marketing approval. The cost includes 
compensation for drug failures during the development phases. The cost is generally 
higher at the later phases of development. Mean out-of-pocket costs for market approved 
drugs were US$15 million in Phase I and $115.2 million in Phase III (DiMasi, Hansen, & 
Grabowski, 2003). One of the approaches to consider mitigating rapidly rising research 
and development costs is to aggressively identify likely drug failures earlier in the 
development process. Thus, positive findings from this study could help to reduce the 
development cost and shorten the development time. 
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In summary, the public health importance this study bears is that it could (a) curb 
the spread of the disease, (b) alleviate the patient’s financial and emotional burdens by 
improving the monitoring of treatment progress and boosting the treatment efficacy 
appropriately, and (c) help the pharmaceutical industry to develop antifungal drugs more 
efficiently and with less cost so that the new drug will have a higher efficacy and be less 
expensive for the patients. 
Summary and Transition 
This chapter articulates the rationale and purpose of the study, provides research 
questions, assumptions, and interprets study significance. Using a large sample size and 
high quality data prospectively collected in well-controlled clinical trials provides a 
unique opportunity to assess the factors associated with achieving a complete cure after a 
standard course of terbinafine oral tablets. This will help fill the gap in the existing 
literature about healthy nail growth and its relationship to treatment success.  
The literature review in the following chapter presents the anatomy of the nail, 
causative agents, clinical presentations, diagnoses, epidemiology, and treatment options. 
These data help us to better understand the challenge antifungal treatments face and 
therefore enhance the importance of this study. Chapter 3 describes the research methods 
utilized, including study design, data sources and statistical analyses. Chapter 4 presents 
study findings. Chapter 5 discusses the results, their implications, recommendations for 







Onychomycosis has been the subject of various studies and clinical trials whose 
purpose has been to show the effectiveness of several treatment options. To better 
understand the disease and its treatment, this chapter will first describe nail anatomy, 
fungi that cause the disease, clinical presentation of the disease, and risk factors 
associated with the infection. It will also summarize treatment options and strategy along 
with presenting research on prognostic factors.  
The literature was identified mainly by extensive searching of various large online 
databases such as Academic Search Premier, CINAHL Plus, PubMed, and Medline. 
Some articles were the result of using a search engine such as Google Scholar or Yahoo. 
Additional articles were identified by reference lists from journal articles and books or 
were obtained from professional journals available at local libraries. Search terms used 
alone or in combination included onychomycosis, dermatophytosis, fungal infection, 
terbinafine, lamisil, nail anatomy, nail disease, prediction, and epidemiology. With few 
exceptions, the majority of articles was published in peer-reviewed journals within the 
last 10 years, and thus reflected the most up-to-date understanding of the disease and 
available antifungal treatment.  
Anatomy of the Nail  
The nail (medically referred as the ungual plate) consists of a nail plate and nail 
bed (Elewski, 1998; Nathan, 2006), as shown in Figure 1. The nail plate is rectangular or 
quadrilateral in shape and is located on the distal end of each toe and finger. A nail 
 15
 
plate’s internal face is seated on the nail bed. Its proximal part is yellow or white in color 
and the quarter-moon-shaped lunula (also called half moon) is often seen in the center. 
The skin between the nail plate and the distal joint in the finger or toe is called the 
proximal fold. The area approximately 5 mm beneath the proximal fold is called the 
matrix and part of it is visible through the lunula. The proximal and lateral folds of the 
skin surrounding the nail form the cuticle and lateral grooves respectively. The end of the 
nail that is no longer attached to the nail bed is called the free edge. Exposure to air 
brings a subtle chemical reaction in the free edge and changes the nail plate to an opaque 
white. The tough skin that curves downward from the plate at the free edge is called 
hyponychium. The tiny crevice between the free edge and the hyponychium is called the 
distal groove (Elewski; Nathan).  
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Figure 1. Nail anatomy as shown from dorsal (top) and lateral (bottom) views. 
The nail plate is hard but flexible, with a convex external surface. It is created by 
a group of highly specialized cells, called onychocytes, in the matrix. The onychocytes 
constantly divide and produce keratin, then undergo a terminal transformation to lose 
their nuclei and form extremely tight bonds with each other as a nail plate. A new nail 
plate pushes the old one further away from the matrix and covers the nail bed (Elewski, 
1998; Nathan, 2006).  
By adhering tightly to the nail plate, the cuticle functions as a protective seal to 




nail unit from pathogens and toxins. The integrity of this structure is essential in 
preventing any fungal invasion because well-aged keratin is the ideal target for fungus, 
especially dermatophytes like Trichophyton rubrum (Elewski, 1998; Nathan, 2006). 
However, the nail becomes more fragile with age. The structure can also be altered by 
injury, certain medical conditions, or long-term exposure to dampness. The altered nail 
integrity provides the opportunity for fungal infection. 
The nail is grown from the matrix and then pushed toward the nail free edge 
(Elewski, 1998). The rate of mitosis in matrix cells determines the nail growth rate. The 
rate can also be influenced by age, health, nail length, and nutritional status (Nathan, 
2006). The average toenail grows 1 mm per month and the average fingernail 2 to 3 mm 
per month (Geyer, Onumah, Uyttendaele, & Scher, 2004). It can take 12 to 18 months to 
grow a complete new great toenail and about 6 months to replace a fingernail. 
Causative Agents 
Nail fungal infections are mainly due to dermatophyte, yeast, or nondermatophyte 
molds (Effendy, Lecha, Chauvin, Chiacchio, & Baran, 2005). They may occur as primary 
diseases caused by pathogens invading the healthy nail plate, or as secondary infections 
of nails with a preexisting disease.  
Dermatophytes belong to “a homogeneous group of keratophilic fungi” (Effendy 
et al., 2005, p. 9). They have the ability to utilize keratin as a nutrient source because they 
possess several enzymes, such as acid proteinases, elastase, keratinases, and other 
proteinases (Torres-Rodríguez & López-Jodra, 2000). They have developed a 
dependency on human or animal infection for the survival and dissemination of their 
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species. The most frequently isolated pathogen from toe onychomycosis is Trichophyton 
rubrum, followed by Trichophyton mentagrophytes and Epidermatophyton floccosum. 
They are responsible for over 70% of all cases (Faergemann & Baran, 2003; Foster, 
Ghannoum, & Elewski, 2004; Haneke & Roseeuw, 1999; Romano, Gianni, & Difonzo, 
2005). Under the microscope, the most reliable identification characters for dermatophyte 
are the microconidia (one-celled and round or pyriform in shape) and/or macroconidia 
(two- or more-celled, smooth-, thin- or thick-walled, and cigar shaped; Suhonen, Dawber, 
& Ellis, 1999, pp 3-18). The growth rate of Trichophyton colonies is slow to moderately 
rapid.  
Humans, especially in the toe web spaces, are the major reservoir for these fungi 
(Buchanan, 2006; Tosti, Hay, & Arenas-Guzman, 2005). Infections by dermatophytes are 
usually caused by the shedding of skin containing viable infectious hyphal elements of 
the fungus. Desquamated skin may remain infectious in the environment for months or 
years. Therefore, transmission may take place by indirect contact long after the infective 
debris has been shed. Substrates like carpet and matting that hold desquamated skin make 
excellent vectors. Thus, transmission of dermatophytes is usually via the feet through 
damp floor surfaces and less frequently via direct person-to-person contact (Buchanan; 
Tosti, Hay, & Arenas-Guzman). Infections of toenail are often chronic and may remain 
subclinical for many years, only to become apparent when spread to another site, usually 
the groin or skin.  
Yeasts “are true fungi that lack hyphae and account for 5.6% of cases” (Effendy 
et al., 2005, p. 2). Pathogens are mainly Candida species with Candida albicans as the 
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most common isolate. Candida is a member of normal flora of skin, mouth, vagina, and 
stool. Being a pathogen and a colonizer, Candida albicans is also found in the 
environment, particularly on leaves, flowers, water, and soil. Under the microscope, it is 
characterized by globs to elongate yeast-like cells (Suhonen et al., 1999, p. 18). Yeasts 
infect more fingernails than toenails. Surveillance data from the United States between 
1999 and 2002 showed that Candida species counted for over 70% of fingernail 
onychomycosis but only less than 7% of toenail onychomycosis (Foster et al., 2004). The 
rate of onychomycosis caused by yeasts was 11% in a European study (Haneke & 
Roseeuw, 1999). 
Molds (nondermatophytic fungi) account for 2.3% to 11% of onychomycosis 
cases (Buchanan, 2006; Foster et al., 2004; Haneke & Roseeuw, 1999). One of the most 
commonly isolated molds is Scopulariopsis brevicaulis (Effendy et al., 2005), which is a 
weakly keratinolytic filamentous (a hyaline) fungus that inhabits soil, plant material, 
feathers, and insects. Molds are distributed worldwide. While they are commonly 
considered contaminants, they also cause infections in immunocompromised patients and 
in the elderly with damaged nail integrity (Effendy et al.).  
Yeasts and molds can be transmitted through direct contact with infected people, 
animals, soil, or surfaces. Superficial infections, particularly of the toenails and the feet, 
also act as reservoirs of the organisms and can spread to other areas of the body and other 
individuals simply by sharing a nail file or clippers. The prevalence of different 
pathogens also depends on factors such as climate, geography, migration, and nail care 
(Buchanan, 2006). Though a single pathogen has caused the majority of onychomycosis 
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cases, the infections of mixed pathogens has been reported as high as 16% (Koussidou et 
al., 2000).  
Clinical Aspects of Disease 
When fungi invade a nail, the nail becomes a safe place for the fungi and protects 
them while they grow in the nail bed and the nail plate. The fungi eat keratin and cause 
the nail to become thickened and yellow. The organic waste materials build up under the 
nail, thus forcing the nail to rise up from the nail bed. Therefore, “onychomycosis is 
characterized by hyperkeratosis (hypertrophy of the skin/nail) of the nail bed, yellow to 
brownish discoloration of the nail plate, onycholysis (separation of the nail from nail bed 
along the lateral margins), and paronychial inflammation” (Werschler, Bondar & 
Armstrong, 2004, p. 146). 
There are five clinical presentations of onychomycosis (Baran & Kaoukhov, 
2005), according to the site and the route of the infection (Hay, 2005): 
1. Distal lateral subungual onychomycosis (DLSO): Stemming from the nail free 
edge hyponychium, the fungus affects the nail bed and the nail plate up to the lateral 
margins of the nail. The infection can gradually reach the matrix. As the disease 
progresses, the nail plate undergoes clinical changes such as thickening and lifting of the 
nail bed, which results in onycholysis and a yellowish discoloration (Baran & Kaoukhov, 
2005; Nathan, 2006, Seebacher et al., 2007). 
2. Endonyx onychomycosis (EO): Stemming from the trimmed nail edge, the 
fungus directly invades the core of nail plate. Both superficial and deep layers of the nail 
plate are infected. The infected nail appears to have a white creamy discoloration and 
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may produce a longitudinal splitting of the nail plate. T. soudanense and T. violaceum are 
the common causative organisms. This is a relatively new category from a more 
comprehensive classification scheme (Baran & Kaoukhov, 2005; Gupta, 2000). 
Previously, DLSO and EO were considered as one category under the distal subungual 
infection (Faergemann & Baran, 2003). 
3. Proximal subungual onychomycosis (PSO): Stemming from the cuticle, the 
fungus, usually Trichophyton rubrum, attacks the proximal nail bed, nail plate, and then 
enters the newly formed nail (Nathan, 2006). Yellow or white patches appear around the 
nail lunula (Hay, 2005). This type of disease is common in immunocompromised persons 
including those with HIV/AIDS. It may, in fact, serve as an indicator of HIV infection 
(Faergemann & Baran, 2003; Ravnborg, Baastrup, & Svejgaard, 1998). Paronychia may 
be associated with secondary PSO, which is due to some molds or Candida. 
4. White superficial onychomycosis (WSO): The fungus directly targets the upper 
layers of the nail plate and produces chalky white or brown patches on the nail surface. 
Eventually, the nail becomes soft and crumby (Baran & Kaoukhov, 2005; Nathan, 2006). 
5. Total dystrophic onychomycosis (TDO). The entire nail plate, even the matrix, 
is infected and results in complete destruction of the nail apparatus. According to some 
researchers, TDO can be “considered as a combination of all infections” (Faergemann & 
Baran, 2003, p. 2). There are two types of TDO: primary and secondary. Primary TDO 
represents simultaneous involvement of all tissues of the nail apparatus. Secondary TDO 
is the result of other destructive nail dystrophy (i.e., DLSO, PSO, WSO or EO). Both 
primary and secondary total dystrophic onychomycosis are difficult to treat and often 
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require combination therapy. Surgical removal of the nail might be considered as a last 
option (Buchannan, 2006).  
The most common type of fungal nail infections is DLSO. PSO is the least 
common form of onychomycosis and is 10 times more frequent in toenails than 
fingernails (Nathan, 2006). WSO, representing about 10% of all cases (Baran & 
Kaoukhov, 2005), is also primarily seen in the toenail.  
It should be noted that two or more nails are commonly affected at the same time. 
On average, 5.5 fingernails or 4.5 toenails were affected according to an Icelandic study 
(Sigurgeirsson, Steingrimsson, & Sveinsdottir, 2002).  
Diagnosis 
Clinical examination and mycological testing play the most important roles in 
detecting onychomycosis. Medical history of the fungal infection and clinical signs are 
important parts of the diagnosis. The most common clinical signs found among 37,397 
clinically diagnosed patients in Europe and East Asia were discoloration and 
hyperkeratosis. The prevalence for each sign was about 54% (Haneke & Roseeuw, 1999). 
The important medical histories from a survey of 209 patients were tinea pedis in 
previous year and scaling on the soles or palms (Fletcher, Hay, & Smeeton, 2004).  
However, mycological results from both microscopy and culture are required for 
disease confirmation (Elewski, 1998; Jaffe, 1998; Seebacher et al., 2007). Since many 
conditions may mimic the clinical appearance of fungal infection, the clinical 
examination must differentiate the signs of onychomycosis from possible nonfungal 
underlying causes such as repeated trauma, psoriasis, lichen planus, local tumors, 
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vascular disorders, inflammatory diseases, and other disorders (Jaffe; Gupta, & Tu, 
2006). It is also essential to determine existence of fungi infection by fungal culture 
before starting an antifungal treatment (Gupta & Tu). The culture needs to identify both 
genus and species of the pathogens because different species respond differently to a 
given antifungal agent (Buchanan, 2006; Scher & Baran, 2003).  
Accuracy of mycological results is closely related to the quality of the nail sample 
(Chauvin, 2005; Elewski, 1998). To obtain a good sample for mycological testing, the 
nail should be disinfected, then scraped from under the surface or clipped at the infected 
area so that the entire nail thickness is sampled. The sample site should be selected 
according to clinical presentation. The most viable hyphae may be found in a hard to 
reach place. Fungus samples collected from the distal portion may be older and 
nonviable. A comparison of 194 samples from different types of onychomycosis using 
the curettage technique showed that the samples from the most proximal parts of affected 
nail had higher culture sensitivity and detected more types of pathogens (Shemer, Trau, 
Davidovici, Grunwald, & Amichai, 2007). 
The amount of the nail sample should be large enough for both microscopy 
examination and culture. The sample for microscopy is treated with potassium hydroxide 
(KOH) to separate the hyphae from keratinocytes as well as kill nonfungal agents, and is 
then examined directly under the microscope within 20 to 30 minutes of sample 
collection (Chauvin, 2005). This process is called the KOH test. If hyphal fragments are 
detected, a fungal culture of the nail sample will be performed to determine the viability 
of the fungus and identify the fungal species.  
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Microscopy and culture may have as high as a 30% false negative result (Scher & 
Baran, 2003) mainly because of poor nail sample collection. New fungi stains and 
calcofluor floresces have been used by some to increase microscopy sensitivity (Hay, 
2005). Histological analysis and polymerase chain reaction have been evaluated as 
diagnostic tools (Gianni et al., 2001). However, “mycological examination remains the 
gold standard technique as it provides the most information at reasonable costs with little 
inconvenience to the patient” (Chauvin, 2005, p. 20). 
Epidemiology 
Prevalence of onychomycosis varied according to study designs. The United 
States Health and Nutrition Examination Survey of 20,749 individuals between 1971 and 
1974 showed a prevalence of nail mycosis of 2.18% (Johnson & Roberts, 1977). About 
8.7% of participants who visited a dermatology clinic in Cleveland, Ohio in 1997 were 
confirmed with onychomycosis (Elewski & Charif, 1997). The prevalence in the United 
Kingdom in early 1990 was about 2.7 % (Roberts, 1992). However, the first large survey 
in Europe between 1997 and 1998 reported the prevalence rate of onychomycosis at over 
26%, much higher than expected (Haneke & Roseeuw, 1999). The incidence of 
onychomycosis, mainly from T. rubrum, increased from 55.2% in 1999 to 78.8% in 2002 
when analyzing 15,381 specimens collected between 1999 and 2002 across the United 
States by a mycology laboratory in Cleveland, Ohio (Foster et al., 2004). Some 
researchers attributed the upward trend to factors such as climate, migration, age, gender, 
obesity, sports, swimming, religious practices, certain professions, overseas travel, 
genetic disposition, concomitant disease, and even fashions (Effendy et al., 2005; 
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Elewski, 2000; Gupta, Cooper, et al., 2004; Pierard, Arrese, Pierard-Franchimont, & 
Quatresooz, 2006). Increasing vigilance among health care workers and patients may also 
play a role in the reporting of a higher prevalence.  
Certain populations might be more susceptible to fungal infections because of 
some predisposing factors. Identified high risk populations were the elderly, patients with 
peripheral arterial disease, diabetes mellitus, immunodeficiency diseases, 
immunocompromised patients, and psoriasis suffers (Baran & Kaoukhov, 2005; 
Buchanan, 2006; Dahdah & Scher, 2006; Gupta, Cooper, et al., 2004; Haneke & 
Roseeuw, 1999, Jaffe, 1998; Tosti et al., 2005). 
Age 
Onychomycosis does not affect all age groups equally. Prevalence and risk of 
onychomycosis increase with advancing age (Haneke & Roseeuw, 1999; Roberts, 1992; 
Svejgaard & Nilsson, 2004). In a North American study, the prevalence of 
onychomycosis steadily increased with each decade of age: 0% for age group 0 to 10 
years, 0.7% for > 10 to 20 years, 3.6% for > 20 to 30 years, 5.6% for > 30 to 40 years, 
9.8% for > 40 to 50 years, 13.7% for > 50 to 60 years, 14.1% for > 60 to 70 years, 21.7% 
for > 70 to 80 years, and 26.9% for those greater than 80 years old (Gupta, 2000). 
European and East Asian surveys revealed that more than 50% of patients who were 65 
years old or older and had suspected foot disease were diagnosed as having 
onychomycosis (Haneke & Roseeuw). The odds of having onychomycosis among 
individuals 50 years old or older were 2.71 times that of the younger age group 
(Sigurgeirsson & Steingrimsson, 2004).  
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However, a few studies showed that the peak prevalence was in the less-than-60-
years-old age group: the highest rate of 25% between age 30 and 40 in Hong Kong (Kam, 
Au, Wong, & Cheung, 1997), the highest rates in the 50-years-old age group for both 
males and females in Greece (Koussidou et al., 2002), and a peak in 45 to 55-years-old 
age group in Italy (Romano et al., 2005). These studies were conducted with patients who 
sought medical help for suspected fungal infections. The results might not represent the 
true prevalence in the general population because of potential selection bias. Some 
onychomycosis patients, especially among the elderly, might be less likely to seek 
medical help. The ratio of estimated prevalence (REP) has been recommended to present 
the results because it uses the general population as a reference. Using REP, the pattern 
of a peak seen in younger age groups was transformed to show an obvious increasing 
trend with aging for any type of onychomycosis, particularly after the age of 70 (Pierard 
et al., 2006). REP = (Onychomycosis per decade of age × total population)/(100 × citizen 
in a defined period of age). 
Children have a lower percentage of onychomycosis. The prevalence of 
onychomycosis in children has been reported between 0% and 2.6%, with a mean of 
0.3%, from different parts of the world (Gupta et al., 1997). However, among 500 
children and adolescents who sought medical help with superficial mycosis in Poland, 
nearly 20% of the cases were confirmed to have onychomycosis (Lange, Roszkiewicz, 
Szczerkowska-Dobosz, Jasie-Walikowska, & Bykowska, 2006). An even higher rate 
(30.7%) of confirmed onychomycosis was reported among children less than 17 years old 
who had nail diseases and provided nail samples to dermatologists between January 1, 
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1990 and December 31, 1999 in Brussels, Belgium (Lateur, Mortaki, & Andre, 2003). 
The youngest child was only 6 weeks old. The toenail was twice as likely to be infected 
as the fingernail among children less than 7 years old. Again these results may not 
represent the prevalence in the general population.  
Individuals with Down syndrome were also more likely to have fungal nail 
infections (Barankin & Guenther, as cited in Gupta & Skinner, 2004). The prevalence of 
onychomycosis has also been found to be greater in human immunodeficiency virus 
(HIV)-infected children (Pros, as cited in Gupta & Skinner). However, no actual data 
were provided by Gupta and Skinner.  
Reasons for onychomycosis to occur more frequently in the older age groups may 
include the following, according to Gupta (2000), Jain and Sehgal (2000), Lateur et al. 
(2003), and Tosti et al. (2005): 
Adults have a slower nail growth rate and larger areas of nail unit conducive for a 
fungal invasion. Cumulative nail traumas experienced during adulthood may also 
increase the risk of fungal infection. For example, ill-fitting shoes or sporting activities 
may damage the physiological seal at the hyponychium. Older individuals become more 
susceptible to fungal infections because of reduced immune competence with aging, 
increased fragility in the nail structure, the presence of peripheral vascular disease, and 
occurrence of multiple episodes of the tinea pedis. Tinea pedis has been observed to 
precede the development of onychomycosis in many instances.  
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Goulden and Goodfield (1997) cited that nail growth decreases by 0.5% per year. 
However, they did not find slow growth to be a predisposing factor for onychomycosis 
when they compared nail growth rates between 36 patients and 22 controls.  
Sex 
There was no uniform report on prevalence of the disease between the sexes for 
onychomycosis. Though men are considered to have a higher risk for onychomycosis 
than women (Gupta, Gupta, et al., 2000; Sigurgeirsson & Steingrimsson, 2004), the 
results varied according to study designs, methods of data collection, and size of the 
study. Effendy et al. (2005) reported that only 45.2% of patients were men in a survey of 
44,972 onychomycosis patients from 16 different countries. The prevalence of 1.8% in 
women and 0.8% in men was cited by Jain and Sehgal (2000). A survey of 43,914 
participants in East Asia showed that more women suffered from onychomycosis (43%) 
than men (39%) (Haneke & Roseeuw, 1999), while a higher prevalence of clinically 
diagnosed onychomycosis in men than women were seen from the European study of 
13,695 participants and the European survey of 22,760 participants in the same project 
(Haneke & Roseeuw). The reported prevalence rates from the study and the survey were 
26% and 27% for men versus 21% and 25% for women, respectively.  
Race  
Onychomycosis affects persons of all races (Blumgerg, 2005). Epidemiological 
studies have been conducted in various parts of the world, though no study was 
conducted to directly assess race as a risk factor. All races are considered susceptible to 
the disease. Because the disease has a multifactorial etiology (Sigurgeirsson & 
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Steingrimsson, 2004), other factors could confound any differences seen between races or 
between studies done in different parts of the world. 
Diabetes 
Diabetes mellitus is a significant risk factor for onychomycosis because of its 
effects on microcirculation. Gupta et al. (1998) evaluated 550 diabetic patients from 
Canada and the United States and found that mycologically confirmed toenail 
onychomycosis was present in 26% of study participants. The occurrence of 
onychomycosis was significantly related to aging and the male gender (both p < 0.0001). 
The odds of having toenail onychomycosis among diabetics were 2.77 times higher than 
normal individuals after controlling for age and sex. The 95% confidence interval (CI) for 
the odds ratio (OR) is between 2.15 and 3.57. The study also identified that family history 
of onychomycosis (p = 0.0001), concurrent intake of immunosuppressive therapy (p = 
0.035), and some of peripheral vascular diseases (p < 0.023) were significant predictors 
for onychomycosis in the diabetic population. 
Psoriasis 
Psoriasis commonly involves nails. Larsen, Haedersdal and Svejgaard (2003) 
investigated the occurrence of onychomycosis among 79 patients with psoriasis versus 
142 patients with other skin diseases in a 15-month period and found that psoriasis 
patients had a significantly higher incidence of nail abnormality than nonpsoriatics 
(82.3% vs. 37.3%, p < 0.01). After microscopy and culture of the scrapings from 
clinically abnormal nails (both fingernails and toenails). 21.5% (17 / 79) of psoriasis 
patients were confirmed to have onychomycosis as compared to 12.7% (18 / 142) of 
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nonpsoriasis patients. However, the difference was not significant (p = 0.18). Psoriasis 
patients also had significantly more severe toenail infection than patients with other skin 
diseases (p < 0.01).  
Sigurgeirsson and Steingrimsson (2004) reported an odds ratio of 2.44 (95% CI: 
1.61–3.72) for psoriasis patients compared to nonpsoriasis patients.  
Clinical signs of psoriasis and onychomycosis often overlap and present difficulty 
in distinguishing between them. Both diseases may coexist in some psoriatic patients. 
Though it has yet to be confirmed, some researchers suggest that “dystrophy nails in 
psoriatic patients lose their natural preventing barrier and therefore are more predisposed 
to fungal infection” (Szepietowski & Salomon, 2007, p. 438).  
HIV Infection 
HIV infection is another major factor in contracting fungal nail infections. In a 
controlled study, more than 30% of patients infected with HIV were found to have 
onychomycosis, compared with 12.6% of controls (Cribier, as cited in Cribier & Bakshi, 
2004). The overall prevalence of onychomycosis among 400 Canadians and 100 
Brazilians infected with HIV was 23.2% (Gupta, Taborda, et al., 2000). More 
specifically, the prevalence rates in Canadians and Brazilians were 24% and 20%, 
respectively. The predominant causative organisms were dematophytes. The predisposing 
factors include a CD4 count of approximately 370, a positive family history of 
onychomycosis, a history of tinea pedis, and walking barefoot around pools. 
In a survey of 250 HIV patients in India (Surjushe et al., 2007), 60 (24%) had 
untreated onychomycosis. Among them, 38 (63.33%) had toenail onychomycosis, 12 
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(20%) had fingernail onychomycosis while 10 (16.66%) had involvement in both the toe 
and finger. Nondermatophyte molds were isolated in 19 (31.66%) patients while 
dermatophytes were only isolated in 13 (21.66%) patients. Eleven of 13 dermatophytes 
were identified as Trichophyton rubrum. Others identified included Trichophyton 
mentagrophytes. Most isolates for nondermatophytes were Candida (n = 12) and 
Aspergillus niger (n = 3). The most common clinical type was total dystrophic 
onychomycosis. Though the survey did not include a comparison group, the overall rate 
is similar to that found by Gupta, Taborda, et al. (2000).  
Transplant Patients 
Since transplant patients require long-term immunosuppressant use, they are also 
at risk for onychomycosis. Virgili, Zampino, and Mantovani (2002) cited a prevalence of 
12.3% among transplant patients. They also stated that the frequency and severity of 
clinical findings increased as the duration of immunosuppression use increased. The most 
common type of clinical presentation is proximal subungual onychomycosis (PSO). 
Similar to HIV infection, PSO is a clinical marker for immunosuppresion.  
Geography 
Onychomycosis exists worldwide. Reported prevalence rates vary from country to 
country. The difference may stem from study design or from data quality. However, Kam 
et al. (1997) considered that climatic conditions may also affect the growth and spread of 
fungi, due to an observed seasonal variation of the occurrence of dermytophytes and 
yeasts as well as a seasonal pattern ascribed to the cases studied in the subtropical climate 
of Hong Kong.  
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Using a self-administered questionnaire and self-diagnosis from a set of 
photographs that depict different severities of onychomycosis, a survey of 9,332 people 
in England in the early part of 1990 found a prevalence of 2.73% (Roberts, 1992). The 
same method was used to interview 10,007 people in Spain by telephone after sample 
photographs had been mailed to the potential study participants between 1992 and 1993 
(Sais, Juegla, & Peyri., 1995). The survey reported a prevalence of 2.6%. Another survey 
of 1,000 healthy volunteers aged 15 or older between April 1997 and December 1997 in 
Madrid produced a prevalence of 3.1% confirmed onychomycosis (95% CI: 2.12–4.38) 
(Palacio, Cuetara, Garau, & Perea, 2006). A study of 1,832 volunteers who visited 12 
primary care doctor offices in North America between June 1997 and May 1998 found 
that 13.8% of the volunteers either had positive mycology, positive culture, or both 
(Ghannoum et al., 2000). A Finnish study reported a prevalence of 8.4% among study 
participants examined by a dermatologist (Heikkila & Stubb, 1995). 
Population studies conducted by Sigurgeirsson, Steingrimsson and Sveinsdottir 
(2002) estimated that the prevalence of positive mycology in the Icelandic population 
was 11.1%. 
The prevalence of onychomycosis in Denmark was estimated at 16.5%. Among 
those studied, 52% were males and 48% were females (Svegjaard & Nilsson, 2004).  
The signs of onychomycosis were seen in 2 out of 10 European patients who had 
visited doctors’ offices. It increased to 4 out of 10 among patients with reported foot 
pathology by the physicians. The prevalence of onychomycosis was similar between 
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European and East Asian populations, with 23% and 22% of the total population, 
respectively (Haneke & Roseeuw, 1999). 
Genetic Factors 
Faergemann, Correia, Nowicki, and Ro (2005) stated that “onychomycosis seems 
to be more common in some families (children and spouses) than others” (p. 17). Though 
this may be the result of intrafamilial transmission, a genetic role can not be totally 
excluded from the reason for a clustered distribution because of the prevalence of 
Trichophyton rubrum infection among parents and children is higher than the prevalence 
among spouses. This may indicate that T. rubrum may prefer certain individuals. A 
pedigree constructed by Zaias (as cited in Faergemann et al., 2005) showed that all 
affected children had at least one parent with distal subungual onychomycosis, which is 
consistent with an autosomal-dominant mode of transmission. 
Faergemann et al. (2005) also cited a study of human leukocyte antigens (HLA) 
among T. rubrum onychomycosis patients in a Jewish population. It found that HLA–
DR52 only existed in all onychomycosis patients, whereas HLA–DR53 only presented in 
all controls. This may suggest that HLA–DR53 plays a key role in protecting against T. 
rubrum onychomycosis in this population. Of course, more studies would be needed to 
confirm the finding. 
Sigurgeirsson and Steingrimsson (2004) found a more than doubled risk for the 
disease if parents had onychomycosis (OR = 2.59; 95% CI: 1.89–3.53), or children had 
onychomycosis (OR = 3.48; 95% CI: 2.05–5.88). However, the risk of onychomycosis 
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was the same between those having spouse (OR = 2.53; 95% CI: 1.72–3.72) and having 
parent as a cosufferer. 
Swimming 
Swimming has been found to favor the occurrence of foot mycoses. 
Onychomycosis of the toenail is at least three times more prevalent in swimmers than in 
the rest of the population in Iceland (Sigurgerisson & Steingrimsson, 2004). 
Other Risk Factors  
Development of onychomycosis is also affected by other factors. Gupta, Gupta, et 
al. (2000) reported that the number of cigarettes consumed per day was an independent 
predictor of the disease. More patients in the heavy smoker group had onychomycosis 
than the lighter smokers. The odds ratio was 1.87 (95% CI: 1.1–1.3) after adjusting for 
age, sex, and peripheral artery disease. The study also found that peripheral artery disease 
was another independent predictor. Patients with peripheral artery disease (as measured 
by ankle-brachial index) were more likely to have onychomycosis (OR = 3.3, 95% CI: 
1.0–6.5). The odds ratio increased to 4.8 after controlling for smoking status. There 
appears to be an interaction between these two risk factors since the crude OR differs 
from adjusted OR by 30%. However, the authors did not explore it further. 
A history of cancer, tinea pedis interdigitalis, and the moccasin form of tinea 
pedis have also been linked to an increased risk of onychomycosis, with odds ratios of 
3.44, 3.93, and 4.26, respectively (Sigurgerisson & Steingrimsson, 2004). 
Torres-Rodríguez and López-Jodra (2000) also presented some risk factors related 
to physical and chemical aggressions. The integrity of the nail and surrounding skin can 
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be damaged by physical or chemical factors and thus facilitate the penetration of different 
fungi. The infection may occur as a result of occupation, personal habits, and other 
considerations. The risk of onychomycosis may be higher for agricultural, construction, 
or iron workers, as well as for bar and restaurant staff, as people in these occupations are 
constantly exposed to microtraumas or moist environments. The risk may also be 
increased for cleaning employees who do not use adequate gloves and have their hands 
wet for long periods of time. Maceration of their skin and nails may be further worsened 
by the use of detergents and caustic substances. Fashion may affect the risk of fungal 
infection as well; nail structure can be compromised with improper footwear. This may 
occur when people wear shoes with sharply pointed toes, shoes that are excessively 
closed, or high heels that displace the body weight toward the toes. Extreme “care of the 
nails” through manicure can also expose a person to a higher risk of the proximal fungal 
infection because of elimination of the cuticle and microtraumas caused by the 
instruments. Personal habits such nail biting or finger sucking also could expose people 
to fungal infection. 
Sigurgeirsson and Steingrimsson (2004) suggested that patients with asthma, 
urticaria, and angioedema were more likely to have onychomycosis. However, it is not 
entirely clear how they are related. Fungal infection may cause an allergic reaction. On 
the other hand, patients with these allergic disorders may be more prone to 
onychomycosis.  
Jain and Sehgal (2000) also found a relationship between different religions to 
occurrence of infection. For example, Candida infection usually involves the fingernails. 
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However, it occurs more on the toenails in Muslims. One possible explanation is that 
fixed rituals requiring Muslims to wash their feet five times a day prior to prayer. 
Treatment 
Though onychomycosis has a high prevalence and could cause serious medical 
problems if left untreated, many sufferers do not take it seriously. One survey found that 
43% of patients did not seek medical advice and 25% were never treated (Jain & Sehgal, 
2000). Because a long course of treatment is required, it has been a challenge for both 
physicians and patients to achieve clinical efficacy.  
Efficacy of treatment is assessed by mycological cure, clinical cure, and complete 
cure achieved about 48–52 weeks after initiation of treatment. Mycological cure is 
defined as having achieved negative results for both KOH testing and mycological 
culture. Clinical cure is defined as complete clearance of a diseased appearance from the 
nail. Complete cure is achieved when a patient has achieved both mycological cure and 
clinical cure.  
It is very rare to have a spontaneous resolution of onychomycosis. The current 
treatment options include systemic, topical, or mechanical therapies. Systemic antifungal 
agents are often considered to be the first line of treatment. Nail removal is considered 
only when there is a significant morbidity or treatment failure.  
Treatment success requires a correct diagnosis because treatment efficacy varies 
by causative organisms (Roberts et al., 2003). Severity of nail infection affects the choice 
of treatment as well. When a nail matrix is infected, the choice of treatment is different 
from cases without matrix involvement. Topical treatment such as nail lacquer has been 
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recommended to treat cases without an infected matrix, whereas oral or combination 
treatments (such as oral plus topical) are recommended for cases with an infected matrix 
(Effendy et al., 2005).  
Topical treatment usually requires daily applications for up to 48 weeks. Though 
it can minimize the systemic exposure of the drug, its efficacy rate is generally lower. 
The reported complete cure rate for Ciclopirox, the topical medication currently available 
in the U.S. market, is between 5.5% and 8.5% after daily application for 48 weeks 
(Aventis Pharmaceutical, 2003). The special challenge for topical treatment arises from 
the nail anatomy itself: nail keratin is not easily permeated, thus topical drugs are 
restricted from reaching infectious organisms. Topical drugs might also be easily 
removed by washing or wiping. Therefore, it is often difficult to maintain effective drug 
concentrations in the nail (Baran & Kaoukhov, 2005).  
Mechanical removal of the nail is not widely used because the procedure does not 
improve the cure significantly. Combinations of surgical nail avulsion and topical 
treatment failed to show improved efficacy in a randomized clinical trial of 40 patients in 
a four-way comparison (Grover, Bansal, Nanda, Reddy, & Kumar, 2007).  
Systemic therapy has one of the highest success rates in the treatment of 
onychomycosis. First-line agents, such as terbinafine and itraconazole, have been 
reported to have mycological cure rates in toenail onychomycosis as high as 80% and 
86%, respectively. However, a complete cure was only achieved in 30–50% of patients 
treated with terbinafine, and in 25–40% of patients treated with itraconazole (Baran & 
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Kaoukhov, 2005). The standard treatment duration for oral antifungal agents is daily 
dosing for up to 12 weeks.  
Various combination therapies have been tested. Though the success rates varied 
from trial to trial, there appeared to be an improvement in treatment outcome (Olafsson, 
Sigurgeirsson, & Baran, 2003; Jennings, Pollak, Harkless, Kianifard, & Tavakkol, 2006).  
Gupta and Tu (2006) also recommend recognizing both nail and patient 
characteristics when planning a treatment strategy. Though it is considered off-label use, 
they suggest that booster therapy (1 week for itraconazole and 4 weeks for terbinafine) 
may be considered at 6 to 9 months after the initiation of a standard course of oral 
treatment: if the diseased area has < 50% reduction in the initial nail plate area, or the 
diseased nail is > 2 mm thickness, or culture results continue to be positive, or > 75% of 
the nail plate is involved. However, this strategy seems to come from empirical evidence 
instead of well designed study findings. They do not mention how big an improvement 
would be expected with the booster treatment.  
Therefore, the treatment strategy will ultimately be a balance between using an 
effective agent, easy application, safety considerations, and treatment duration.  
Many studies assessed the efficacy of antifungal treatment (Drake et al., 1997, 
Sigurgeirsson et al., 2006; Tang, Chong, Leung, Ho, & Wong, 2000; Warshaw et al., 
2005). Some studies assessed predicting factors related to the treatment outcome 
(Sigurgeirsson, Paul, Curran, and Evans, 2002). Among these studies, commonly 
examined factors were age, sex, extent of the disease, infection in the nail matrix area, 
treatment history, and duration of the infection. 
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Sigurgeirsson, Paul, et al. (2002) studied factors associated with mycological cure 
72 weeks after starting a full course of treatment among 496 patients participating in a 
randomized clinical trial. They concluded that the results of mycological culture at Week 
12 and 24 and KOH test at Week 24 can help with early identification of patients who 
would fail the conventional systemic oral antifungal treatment. A negative culture at 
either Week 12 or 24 was significantly associated with continued mycological cure at 
Week 72 (p < 0.05). The percentage change in infected nail area at Week 24 after 
initiating treatment was positive, but was small in the magnitude associated with 
mycological cure at Week 72.  
Disease severity, especially infection of matrix, may be a factor for failure of 
achieving a complete cure. When the nail matrix is involved, the onychocytes may be 
destroyed so that it will become much more difficult for this type of patient to grow a 
completely new healthy nail. However, matrix involvement is often difficult to assess 
because nail appearance is not a good indicator for the infection of the matrix. Therefore, 
its value as a treatment predictor is often limited. 
Treatment noncompliance may also be a factor contributing to treatment failure. 
Noncompliance includes failure to follow a dose regimen, such as skipping doses, 
underdosing, or early termination of treatment.  
Other factors that may indicate a poor treatment outcome include lateral nail 
disease and certain types of nail morphology such as notable streaks (Scher & Baran, 
2003). Treatment outcome may also be affected by concomitant disease or treatment, or 




Treatment failure may also be attributed to reinfection or relapse. Recurrence of 
onychomycosis is fairly common. Tosti, Piraccini, Stinchi, and Colombo (1998) found 
that 22.2% of patients experienced a relapse after achieving successful treatment with 
systemic antifungals. The relapse rate increased from 8.3% at month 12 to 19.4% at 
month 24 and to 22.2% at month 36.  
The risk factors for disease recurrence are similar to those for treatment failure. 
Scher and Baran (2003) summarized that potential factors for recurrence include age 
greater than 60 years old, family history, occupation, lifestyle, inherent susceptibility to 
fungal infection such as two-feet-one-hand syndrome (defined as bilateral plantar tinea 
pedis, fungal infection of the foot, with coexistent unilateral tinea manuum, fungal 
infection of the hand), concomitant diseases such as peripheral vascular disease or tinea 
pedis, early termination of treatment or use of an inappropriate dose. Elderly with 
arthritis or bone abnormalities may likely have recurrence due to physical trauma.  
Also, recurrence may be the result of ineffective treatment. As mentioned by Tosti 
et al. (2005), there is lack of effective treatment for onychomycosis from molds or nails 
with notable streaks.  
Since a history of tinea pedis has been linked to the onychomycosis, 
concomitantly treating the tinea pedis and other skin dermatomycoses may help prevent 
the recurrence of the onychomycosis.  
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Can Treatment Success Be Predicted Early? 
In order to achieve a complete cure (mycological cure and clinical cure) , a new 
nail must be grown--from proximal to distal--to replace the diseased nail and make it 
devoid of any further fungal infection. The time required for visible clearance of the 
infection depends on the rate of nail growth and the type of clinical presentation. Such 
rates should be relatively consistent within a patient during this limited study time period. 
Thus, there is a possibility of predicting treatment success based on the rate of healthy 
nail growth during the early treatment phase. 
Some factors have been found to affect nail growth. Onychomycosis had been 
found to slow down the growth rate, but antifungal treatment could speed nail growth 
(Geyer et al., 2004). Yu, Kwon, Oh, and Kim (2004) compared the growth rate in one 
diseased great toenail in one foot versus normal great toenail growth on another foot for 
the same patient. They found that a diseased toenail had a slower growth rate than an 
unaffected great toenail if affected area was spread over 50% of the nail. After the 
affected nail became normal following antifungal treatment, such differences 
disappeared. So disease severity could affect treatment success by affecting nail growth. 
It should noted that about 5–10% of severe onychomycosis patients will still have an 
abnormal nail surface even when the mycological cure is maintained (Hay, 2005). 
Can the treatment outcome be predicted by disease features or progress during 
treatment? Sommer et al. (2003) tried to answer this question in a small study. The 
authors randomized 35 patients to receive either 125 mg or 250 mg oral terbinafine for 12 
weeks. They then assessed the mycological cure and clinical cure at Week 48 in relation 
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to baseline characteristics such as the length of unaffected nail, hyperkeratosis, 
onycholysis, presence of a dermatophytoma, and the growth rate of unaffected nail over 
the course of the study. The study failed to produce any significant predictors. It could be 
that the study was not properly powered to detect any meaningful difference.  
As yet, no study has provided convincing evidence to either prove or disprove the 
link between the nail growth at early stage of treatment and a complete cure as a final 
treatment outcome. A study with a large sample size may provide a better and more 
reliable assessment. Therefore, this proposed study will aim to examine the relationship 
between nail growth during the study period and the final treatment outcome after a 
standard course of terbinafine treatment. If there is a positive relationship between the 
nail growth rate and a complete cure, the study will also explore the best indicator and the 








This population-based study was designed to explore the relationship between nail 
growth patterns during the trial period and the treatment outcome up to 48 weeks after the 
initiation of treatment. Nail growth patterns were compared between patients who 
achieved complete cure and patients who failed treatment, with and without adjusting for 
factors such as age, gender, disease severity, and antifungal treatment history. The 
treatment pattern is referred to as either the actual length or alternatively as the proportion 
of total healthy nail grown. It has been postulated that a positive response to treatment 
will be reflected in the growth of healthy nail along with negative mycological results. 
This chapter describes the study design, study population and sample size, hypotheses, 
data analysis, data source, and protection of human subjects. 
Research Design 
Using only patients treated with the standard oral antifungal agent terbinafine 
from two identically designed Phase III randomized clinical trials that assessed drug 
efficacy, two groups were created based on the achievement of complete cure during the 
trial period: cured or failed. Selected factors at each scheduled trial visit were compared 
between patients who were cured and patients who failed treatment in order to explore 
the important factors that may predict the achievement of a complete cure.  
There were a total of 998 patients treated with terbinafine in two Phase III global 
clinical trials. Patients were enrolled in the studies from three continents between 
September 2002 and October 2002. After a 6-week screening period, patients were 
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treated for 12 weeks and observed for an additional 36 weeks, making the total trial 
duration for a patient 54 weeks. The patients were seen by the trial investigators at office 
visits scheduled for Weeks 4, 8, and 12 during the treatment period, and for Weeks 16, 
24, 36, and 48 during the follow-up period. Data gathered at each of these visits included 
photographs of the nail with required markings, clinical assessment of the nail, 
mycological testing results, and safety parameters. The primary efficacy endpoint was the 
achievement of complete cure (both mycological cure and clinical cure) on the target 
great toenail by Week 48; a dichotomous variable with a yes or no answer. Complete cure 
was defined as the growth of a completely healthy target great toenail with negative KOH 
microscopy and negative culture for dermatophytes from the target great toenail sample. 
The trials were completed in November 2003. Among 998 patients treated with 
terbinafine, 798 of them completed the trials without committing major protocol 
violations.  
Since the data were gathered under well-controlled clinical trial settings, the 
quality of data was well suited for quantitative analysis. Independent variables for this 
research included patient demographics (age, race, sex, baseline body weight, country or 
trial center), baseline disease characteristics (onycholysis, percentage of nail infected, 
antifungal treatment history), mycological test results at each scheduled visit, healthy nail 
growth on the target great toenail at each scheduled visit, and number of days dosed with 
trial medication regardless of dosing pattern. 
The primary efficacy endpoint–complete or incomplete cure–was the dependent 
variable for the study.  
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Study Population and Sample 
Any trial participant who met all of the following eligibility criteria were selected 
for this study. These criteria included any patients who: 
1. Met the original trial inclusion and exclusion criteria. 
2. Had been treated with terbinafine and received 80–120% of the prescribed dose 
regimen regardless the missing pattern. 
3. Had been observed for the entire 48 weeks after the initiation of the treatment. 
4. Had provided sufficient measurements of the healthy target great toenail 
growth (i.e., the researcher needed to have at least the measurements obtained at baseline, 
Week 12, 16, and 24 visits) during the trial period. Prior to trial randomization, an 
infected great toenail was identified as the target to monitor the treatment response during 
the trial. This great toenail was referred as the “target great toenail” or simply called 
“target toenail”. 
The original trial protocol limited the trial participants to those who were 18 years 
of age or older; had a great toenail diagnosed as onychomycosis from dermatophytes; and 
had a confirmed growth of the infected great toenail of a minimum of 1 mm during the 6-
week screening period, a sign showing that the infected great toenail was capable of 
regrowth. Though patients with spikes, lateral involvement, and white superficial 
onychomycosis were included in the trial, such data were not recorded in the database.  
The trials also implemented a set of exclusion criteria to minimize factors that 
could interfere with efficacy assessments or jeopardize patient safety. Patients were 
excluded if they had received systemic or topic antifungal therapy in a specified time 
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period prior to screening, or if they had active psoriasis. Patients were also excluded if 
they had any conditions that could affect compliance with administration of the 
medication or the absorption, metabolism, or excretion of the trial drug.   
The trial was powered to show the noninferiority margin of 10% with 80% power 
at a 5% significance level. The planned sample size for each trial was 1,250 screened 
patients, 900 enrolled patients, and 740 evaluable patients. For each trial, 370 patients 
would be treated with the standard terbinafine treatment.  
The original trials aimed to compare the efficacy of two different drugs. The 
results were published by Sigurgeirsson et al. (2006). However, this study focused only 
on patients treated with terbinafine. It measured the growth of healthy nail over time, 
which was omitted from the original trial, and associated growth with the achievement of 
a complete cure among these patients. 
The sample size used for this study was not based on statistical considerations. It 
was based upon data availability and fulfillment of the study entry criteria.  
Data Source and Quality 
The original trial data were collected using a validated electronic system that met 
high industrial standards and regulatory requirements. The data were recorded according 
to the protocol specifications and were managed by skilled personnel. Data discrepancies 
were checked and verified. All data points were certified to be complete and accurate by 
the trial investigators.  
Mycology samples were processed through two central mycology laboratories and 
the results were sent electronically to the sponsor. The database was locked after the data 
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had been declared to be complete and accurate, then the treatment code was revealed for 
the analysis.  
All data points, except the length of healthy nail growth, were obtained directly 
from the clinical trial database. Length of clear healthy nail at each visit was measured 
manually by this researcher from the digitalized photos of the target toenails taken for 
that visit. Each photo contains a ruler and the markings of all borders that indicate 
diseased versus healthy areas. The length of healthy nail was the shortest distance in 
millimeters (mm) from the middle of the proximal nail fold to a horizontal line of the 
lowest part of the healthy-diseased border (see Figure 2). This was the same definition 
used by Sommer et al (2003). A divider caliper was used to measure the distance and 
then compared with the embedded ruler to obtain the length in millimeters. For each 
patient, the length of the entire target toenail was also measured using the same method to 
indicate the size of the fully grown target great toenail. The measurements were reviewed 
by a dermatologist associated with the original clinical trials. These lengths were used to 
create two variables for the analysis:  
1. Length of healthy target toenail regrown. It was defined as the change from 
baseline to postbaseline in the shortest length of healthy target toenail grown. 
2. The proportion of total target toenail length regrown as healthy. It was defined 
as change from the baseline to postbaseline as the ratio of the length of healthy target 
toenail regrown over total target toenail length  
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Figure 2. Digitalized photograph with the markings of the diseased and healthy nail 
areas. It depicts the measurements of the shortest length of healthy nail growth and total 
full nail length. 
 
A previous study (Sommer et al, 2003) failed to demonstrate the link between the 
treatment outcome and the healthy nail growth rate. The failure was partially attributed to 
the small sample size of 35 patients. This research reassessed the relationship using a 
much larger sample size along with other possible predictors. Specifically, the final 
treatment outcome–complete cure–was evaluated against (a) length of healthy toenail 
regrown and (b) proportion of the total toenail regrown as healthy. Each of these 






What is the association between final treatment outcome and the length of healthy 
nail regrown during trial period?  
Null Hypothesis: There is no association between the achievement of complete 
cure and change in the length of healthy nail growth at any point in time during the 48-
week period. 
Alternative Hypothesis: There is an association between the achievement of 
complete cure and change in the length of healthy nail growth during the 48-week period. 
The assumption was that if the nail grows uniformly and pushes the nail evenly 
through the nail bed, the change in healthy nail length will reflect the time needed to 
grow a completely healthy new nail. The shortest distance between the proximal nail fold 
and healthy-disease border would require the longest time to replace the diseased nail and 
should be a good predictor of the final treatment outcome.  
Second Hypothesis 
What is the association between the final treatment outcome and the proportion of 
total nail regrown as healthy over the trial period?  
Null Hypothesis: There is no association between the achievement of complete 
cure and the change in the percentage of total full nail length grown as healthy at any 
point in time during the 48-week period. 
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Alternative Hypothesis: There is an association between the achievement of 
complete cure and the change in the percentage of total full nail length grown as healthy 
at any point in time during the 48-week period. 
Since healthy nail length alone does not take into account nail size and the 
variable amount of time needed to grow a different size of new nail, the length of healthy 
new nail expressed as the proportion of total full nail length may be a better reflection of 
the time associated with achievement of the complete cure. Also, the study would 
identify the earliest point in time at which the treatment outcome could be predicted by 
each of the variables.  
Data Analysis 
Descriptive statistics were used to describe the study population by final treatment 
outcome. Statistics for continuous variables were total sample, mean, median, standard 
deviation, minimum, and maximum. Statistics for categorical variables were subsample 
and percentage.  





Summary of All Proposed Analyses 
Topic Analysis Statistics  
Demographic information Descriptive analysis. Continuous variable: N, M, Mdn, 
SD, Range  
Categorical variables: n % 
Baseline disease characteristics Descriptive analysis. Continuous variable: N, M, Mdn, 
SD,Range 
Categorical variables: n % 
Mean change in healthy nail 
growth from the baseline at each 
scheduled visit 
t test M, SD, p-value 
Effect of prognostic factors on 
complete cure 
Multivariate Logistic Regression OR, 95%CI, 
 
The means for the variable of healthy nail regrowth during the trial period were 
presented in a line plot or a summary table by the treatment outcome. These means were 
compared by the treatment outcome using a two-sided t test at each scheduled visit. The 
results were evaluated at a 5% significance level. 
Also, the associations of the treatment outcome and the healthy nail regrowth 
variables were assessed using multivariate logistic regressions adjusting for other 
independent variables. Because the disease affects more in the elderly (> 65 years old) 
than younger ones (< 40 years old), the age was divided into three groups (< 40, 40–65, > 
65). Therefore, two dummy variables for age groups were used in the logistic regression. 




Complete cure (yes/no) = healthy nail regrown parameter at a visit (mm) + KOH 
at the same visit (negative/positive) + culture at the same visit (negative/positive) + age 
group 1 (< 40 vs. > 65) + age group 2 (40–65 vs. > 65) + sex (male/female) + percentage 
of nail infected at baseline (%)+ the history of antifungal treatment (no/yes) + sign of nail 
onycholysis (no/yes) + length of nail grown at baseline period (mm) + % of expected trial 
drug were taken (%). 
Total nail size was also an independent variable when assessing Hypothesis 1: 
change in the length of healthy nail from the baseline. 
No adjustment was made for multiple hypotheses testing because the main 
purpose of the research was to explore better predictors for the treatment outcome. For 
the same purpose, only factors at early phase of the trial would be meaningful to predict 
the treatment outcome. The key point in time for this prediction would be around Week 
12, the end of the treatment period. 
The best point in time was selected based on OR for the nail growth. Once the 
best point was selected, the insignificant variables in the initial model were deleted to 
produce a final model. 
The analysis was done using SAS procedures such as frequency, means, t test, and 
logistic regression in SAS version 8.02. 
Protection of Human Subjects 
These two clinical trials were designed and implemented in accordance with the 
most current guidelines available for good clinical practice and applicable regulations for 
trials on medicinal products in the European Community and United States, and with the 
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ethical principles specified in the Declaration of Helsinki. The trial was approved by the 
appropriate Institutional Review Board (IRB) at each trial site. All patients provided 
written informed consent prior to entering the trial. 
Each patient in the original trial was uniquely identified by his or her own trial ID 
number. The clinical trial data did not contain sufficiently information to identify any 
participant. Therefore, the participants for this study were considered completely 
anonymous. 
Access rights to the database were granted by the original trial sponsor in writing. 
The written letter was considered sufficient by Walden University IRB. The construction 
of the database and analysis commenced after the final approval from the IRB committee 
(IRB Certification # 07-21-08-0324060). 
In line with Walden University’s commitment to social change, the study results 
will be disseminated via publications from the dissertation as abstract and peer-reviewed 
journal article. 
The following section presents the results from the statistical analysis related to 





A total of 750 patients met the inclusion criteria for this study. Among them, 178 
patients achieved complete cures during the course of the trial. This included 23 patients 
who relapsed at a later stage of the trial period: One patient relapsed at Week 24 after 
having achieved complete cure at Week 16; 11 patients had complete cure at Week 24 
but relapsed at Week 36 (n = 6) or Week 48 (n = 5); and another 11 patients achieved 
complete cure at Week 36, but failed to maintain a total healthy nail at Week 48. Since 
the rate of healthy nail growth was used to predict the achievement of complete cure, the 
nail growth was only measured before the relapse occurred. This approach was taken 
under the assumption that the relapse was not associated with baseline risk factors. It was 
only associated with other factors after the cure was achieved. To assess what factors 
contributed to the relapse, a future research project will be necessary. 
Patients for this study came from 15 countries: 417 (55.6%) patients from the 
United States; 98 (13.1%) from Iceland; 64 (8.5%) from Germany; 23 (3.0 %) from 
Guatemala; 21 (2.8%) from Peru; 18 (2.4%) each from Canada, Finland, France, and 
Slovakia; 15 (2%) from Norway; 11 (1.5%) from Brazil; 10 (1.3%) from Poland; 8 (1%) 
from Mexico; 6 (0.8%) from Italy; and 5 (0.7% ) from Columbia. 
As shown in Table 2, the mean age of patients who achieved a complete cure was 
6 years younger than patients who failed: 45.7 years old versus 51.7 years old, 
respectively. The difference was statistically significant (p < 0.001). Also, cured patients 
were more likely to be female, have a lower body weight, and have a smaller body 
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surface area. Body weight had not been linked to the treatment success in other studies. 
Caucasian patients had a lower cure rate than other races, although they represented the 
majority of patients. Caucasians comprised 75% or more of both the cured and failed 
groups. 
Table 2 
Baseline Characteristics  
 
Characteristics Cured 
N = 178 
Failed 














































































* p-value is obtained from t test for continuous variable or χ² test for categorical variable. 
Patients who failed to achieve a complete cure had more severe disease, with a 
higher percentage of nail area infected and longer disease duration. The average 
percentage of diseased area on the targeted toenail was 60.0% in cured patients, and 
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65.5% in failed patients. The difference was small but statistically significant with a p-
value of 0.0159 (see Table 3). The failed patients were also more likely to have prior 
antifungal treatment, presence of hyperkeratosis, and presence of onycholysis on the 
target big toenail. As shown in Table 3, only 18% of cured patients had been treated 
before, compared with 27.3% of failed patients (p = 0.0125). The sign of hyperkeratosis 
existed in 88.2% and 93.7% of cured patients and failed patients, respectively. 
Overall, the average total length for a big toenail was 14 mm with SD = 2.41 mm. 
The shortest toenail was 4 mm and the longest one was 24 mm. The mean length was 
13.4 mm (SD = 2.44 mm) for cured patients, and 14.4 mm (SD = 2.36 mm) for failed 
patients. The difference of 1 mm between two groups was statistically significant (p < 
0.0001).  
Before initiating the treatment, the mean length of healthy nail for all patients was 
1.87 mm (SD = 2.11 mm). There was no difference between cured and failed patients 
with mean lengths of 1.85 mm and 1.87 mm, respectively. There also was no difference 
between the two groups if mean length of healthy nail was expressed as the percentage of 
the total full nail length. The mean value for cured patients was 13.5% and for failed 




Disease Characteristics  
 
Characteristics Cured 
N = 178 
Failed 
N = 572 
 p-value* 




















































Had sign of onycholysis 144 (80.9%) 482 (84.3%) 0.2910 
Had sign of discoloration 172 (96.6%) 558 (97.6%) 0.5043 
Had sign of hyperkeratosis 157 (88.2%) 536 (93.7%) 0.0155 
Had used antifungal treatment before 32 (18.0%) 156 (27.3%) 0.0125 
























Percent of total full nail length as 
healthy 

















Hypothesis 1 aimed to evaluate the association between the growth of the healthy 
nail in length during the trial period and the achievement of complete cure by Week 48, 
after adjusting for other risk factors. The length of healthy nail was measured by the 
shortest distance between the proximal nail fold and the healthy-diseased boarder as 
depicted in Figure 2. The growth of healthy nail in length was measured by the change 
from baseline in the length of the healthy nail. It was referred to as the length of healthy 
nail regrown. 
Mean growth (changes from baseline in the length of the healthy nail) among 
cured patients and failed ones at scheduled study visits are presented in Figure 3 and 
Table 4. Starting at Week 4 and throughout the trial period, the growth of the healthy nail 
among cured patients appeared to be at a faster pace than that seen among failed patients 
(see Figure 3). The mean growth among cured patients was almost twice that of failed 
patients throughout the trial period (see Table 4). At Week 4, the mean growth of the 
healthy nail in the cured group was 1.23 mm versus 0.64 mm in the failed group, a ratio 
of 1.9. At Week 12, the difference was still kept at 1.87 times with a mean growth of 3.56 
mm in the cured group and 1.90 mm in the failed group. By Week 36, the mean growth 
of the healthy nail in the cured group was more than twice that of the failed group (9.41 
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Figure 3. Line graph showing the mean changes in healthy nail growth (mm) during the 






Comparison of the Mean Change (mm) in Healthy Nail Length During the Trial Period 
Between Cured Patients and Failed Patients  
Week Cured            
Mean (SD) 
Failed        
Mean (SD) 
p-value 
4 1.23 (1.41) 0.64 (1.42) < 0.001 
8 2.32 (1.72) 1.31 (1.66) < 0.001 
12 3.56 (2.08) 1.90 (1.82) < 0.001 
16 4.80 (2.38) 2.64 (2.25) < 0.001 
24 6.82 (3.12) 3.63 (2.82) < 0.001 
36 9.45 (3.06) 4.18 (3.68) < 0.001 
48 11.53 (3.01) 4.62 (4.45) < 0.001 
 
When measuring the rate of healthy nail growth, the average increases in healthy 
nail length at 4-week intervals among cured patients were 1.23 mm at Week 4, 1.09 mm 
at Week 8, 1.24 mm at Week 12 and 16, 1.01 mm at Week 24, 0.88 mm at Week 36, and 
0.69 mm at Week 48. The average growth rates among failed patients at the 
corresponding intervals were 0.64 mm, 0.67 mm, 0.59 mm, 0.74 mm, 0.5 mm, 0.18 mm, 
and 0.15 mm, respectively. The growth rate of the healthy nail was much faster in cured 
patients than in failed ones. Healthy nails grew faster during the first 16 weeks than 
during the last 32 weeks of the trial. 
The null hypothesis of no association between the achievement of complete cure 
and the growth of healthy nail length during the trial period was assessed using a similar 
multivariate logistic regression at each of the scheduled visits (Weeks 4, 8, 12, 16, 24, 
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and 36) adjusting for the same set of factors, such as age groups (< 40 vs. > 65; 40–65 vs. 
> 65), duration of current onychomycosis (months), percentage of prescribed drug taken 
(%), sign of onycholysis on the target big toenail (no vs. yes), history of antifungal 
treatment (no vs. yes), sex (female vs. male), percentage of nail infected prior to start the 
treatment (%), length of nail grown during the baseline period (mm), KOH microscopy 
result at the corresponding visit (negative vs. positive), mycological culture result at the 
corresponding visit (negative vs. positive), and total full nail length (mm). Table 5 
summarizes the adjusted odds ratio (OR) and 95% confidence interval (CI) of healthy 
nail growth for all scheduled visits. It shows that change in the length of healthy nail 
growth was significantly associated with the achievement of complete cure at all visits. 
Depending on which visit was assessed, the odds of achieving complete cure were 
increased by 1.4 to 1.6 times for each millimeter of healthy nail growth. So the null 
hypothesis was rejected. There was a strong association between the change in the 
healthy nail length and the achievement of complete cure after adjusting for other risk 
factors. 
Comparing crude OR and adjusted OR, the percent change between the two per 
formula from Sullivan (2005) was less than 5% for each visit. A 10% threshold has been 
suggested to judge if a factor was an important confounder (Sullivan; Varkevisser, 
Pathmanathan, & Brownlee, 2003, P. 87). Therefore the relationship between the clear 
nail length and the treatment status was not strongly confounded by other factors. Also 
the interaction terms between clear nail length and each of the other risk factors were not 




Odds Ratios at Each Trial Visit for Clear Nail Growth Associated With the Complete 
Cure  
 
Week Crude OR Adjusted 
OR* 
95% CI % change between crude 
and adj. ORs ** 
4 1.352 1.349 1.160 1.569 0.22% 
8 1.437 1.510 1.328 1.717 4.83% 
12 1.602 1.630 1.443 1.841 1.72% 
16 1.509 1.527 1.380 1.691 1.18% 
24 1.456 1.489 1.369 1.619 2.22% 
36 1.510 1.584 1.453 1.728 4.67% 
* adjusted for age group, duration of current onychomycosis, percent of prescribed drug 
taken, sign of onycholysis on the target big toenail, history of antifungal treatment, sex, 
percent nail infected prior to start the treatment, length of nail grown during the baseline 
period, KOH microscopy result at corresponding visit, mycological culture result at 
corresponding visit, and total full nail length. 
** %change = (|cOR-aOR|/aOR) x 100. 
 
Since the length at Week 12 produced the biggest OR (1.630) after adjusting for 
other risk factors, Table 6 presents the results of full logistic regression model at Week 
12. This model fitted the data well. The p-value from Hosmer and Lemeshow goodness-
of-fit test was 0.6412. The analysis showed that less-than-40-year-old patients were more 
than two and half times likely to be cured than 65-year-old patients. Patients who were 40 
to 65 years old were also nearly twice as likely to be cured as 65-year-old patients. 
Treatment-naive patients (patients who have not received antifungal treatment for 
onychomycosis) had a higher chance of cure (OR = 1.8, 95%CI: 1.06–3.01). Shorter nail 
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size and smaller area of infection were also significantly linked to the cure with OR of 
0.81 (95% CI: 0.73–0.89) and 0.99 (95% CI: 0.980–0.998), respectively. The odds of 
cure were also higher for females and for patients with negative mycological culture 




Odds Ratio and 95% Confidence Interval of Risk Factors at Week 12 in Association With 
Achievement of the Complete Cure From the Full Logistic Model 
Factors OR 95% CI p-value 
Age <40 vs. > 65  2.698 1.184 6.150 0.0182 
Age 40–65 vs. > 65 1.965 0.919 4.204 0.0816 
Duration of current Onychomycosis (months) 0.999 0.997 1.001 0.2698 
Percent of prescribed drug taken (%) 1.017 0.968 1.068 0.5072 
Sign of onycholysis (no vs. yes) 1.144 0.647 2.025 0.6431 
History of antifungal treatment (no vs. yes) 1.784 1.058 3.007 0.0298 
Sex (female vs. male) 1.418 0.909 2.212 0.1238 
Percent nail infected prior to start the treatment 
(%) 
0.989 0.980 0.998 0.0151 
Length of nail grown during baseline (mm) 1.169 0.953 1.434 0.1350 
KOH at Week 12 (negative vs. positive) 0.613 0.263 1.427 0.2564 
Culture at Week 12 (negative vs. positive) 1.395 0.904 2.155 0.1329 
Total full nail length (mm) 0.807 0.733 0.888 <0.0001
Change in healthy nail length at Week 12 from 
baseline (mm) 





Because not all risk factors in the full model were significantly associated with 
the treatment outcome, those with p-values greater than 0.1 were deleted from the final 
model. The final model fitted the data equally well. The p-value from Hosmer and 
Lemeshow goodness-of-fit test was 0.1571. The risk estimates for all variables in the 
final model were very similar to ones from the full model (see Table 7). Again, patients 
who were younger in age, treatment-naive, who have a smaller percentage of nail 
infected, or who have smaller nail sizes were significantly associated with achieving a 
complete cure during the 48-week trial period.  
Table 7 
Odds Ratio and 95% Confidence Interval of Risk Factors at Week 12 in Association With 
Achievement of the Complete Cure From the Final Logistic Model  
Factors OR 95% CI p-value 
Age <40 vs. > 65  3.136 1.432 6.870 0.0043 
Age 40–65 vs. >65 2.170 1.033 4.559 0.0408 
History of antifungal treatment (No vs. Yes) 1.719 1.032 2.865 0.0375 
Percent nail infected prior to start the treatment 0.988 0.980 0.997 0.0093 
Total full nail length (mm) 0.807 0.737 0.884 <0.0001
Change in length of clear nail grown at Week 
12 from baseline (mm) 
1.627 1.443 1.833 <0.0001
 
The negative mycological culture result at Week 16 was the first time to show a 
significant association with a complete cure (OR = 1.948, 95% CI: 1.218–3.117). The 
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association became stronger at Week 24 (OR = 3.420, 95% CI: 1.760–6.649), but it was 
no longer statistically significant at Week 36 with OR of 2.211 and 95% CI between 
0.882 and 5.543. 
Negative microscopy results only became significantly associated with a complete 
cure at Week 36 (OR = 2.846, 95% CI: 1.637–4.950). This is a reasonable finding 
because fungal hyphae can still be detected under the microscope even long after fungi 
have been killed and culture result becomes negative.  
Hypothesis 2 
The purpose of Hypothesis 2 was to evaluate if the percentage of the total nail 
grown as healthy nail was associated with the achievement of a complete cure after 
adjusting for other risk factors. The percentage was calculated with the length of healthy 
nail divided by the total full nail length. Change from baseline in the percentage was used 
for all analyses related to Hypothesis 2. Comparing the results between Hypothesis 1 and 
Hypothesis 2 might also provide a clue about which variable would be a better predictor 
for the achievement of a complete cure. 
Similar analytical approaches to Hypothesis 1 were used to test Hypothesis 2. The 
results are presented in Figure 4 and Table 8–11, which are in the same order as the 
results for Hypothesis 1.  
Figure 4 shows the mean changes in percentage of nail regrown as healthy nail 
during the course of trial. The percentage of total full nail length regrown as healthy was 
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Figure 4. Line graph showing changes in percentage of total nail regrown as healthy nail 
during the trial period, by treatment outcome. 
 
The average percentage of total nail grown as healthy nail was nearly twice as 
high in the cured group as in the failed group at each scheduled trial visit (see Table 8). 
The increase in the percentage during the first 16 weeks was about 8–9.7% for every 4-
week interval in the cured group compared to 4.7–5.3% in the failed group. The growth 
rate slowed down a little during Week 24 to Week 48. The increases in the cured group 
were 7.3%, 6.7%, and 4.4% for every 4-week interval during this period, respectively. 





Comparison of Percentage of Total Nail Regrown as Healthy Nail During the Trial 
Period Between Cured Patients and Failed Ones 
Week Cured             
mean (SD) 
Failed              
mean (SD) 
p-value 
4 9.52 (10.70) 4.61 (10.09) < 0.001 
8 17.52 (12.77) 9.43 (11.97) < 0.001 
12 26.85 (15.05) 13.51 (12.91) < 0.001 
16 36.56 (17.82) 18.17 (16.04) < 0.001 
24 51.30 (22.33) 25.65 (19.99) < 0.001 
36 71.66 (21.50) 29.30 (25.42) < 0.001 
48 85.45 (16.95) 32.36 (30.73) < 0.001 
 
The null hypothesis of no association between the growth in percentage of total 
full nail length and the achievement of complete cure during the trial period was tested 
using multivariate logistic regression at each scheduled visit, controlling for factors such 
as age group (< 40 vs. > 65; 40–65 vs. > 65), duration of current onychomycosis 
(months), percentage of prescribed drug taken (%), sign of onycholysis on target big 
toenail (no vs. yes), history of antifungal treatment (no vs. yes), sex (female vs. male), 
percentage of nail infected prior to start the treatment (%), length of nail grown during 
the baseline period (mm), KOH result at corresponding visit (negative vs. positive), and 
mycological culture result at corresponding visit (negative vs. positive).This was a 
similar model to Hypothesis 1 except total full nail length was removed because the total 
full nail length was already part of the outcome variable. Table 9 presents the adjusted 
OR and 95% CI for the percentage of total nail grown as healthy at each scheduled visit. 
 69
 
Adjusted ORs were between 1.045 and 1.074 throughout the trial period. All 95% CIs 
were above 1 (see Table 9). Starting at Week 4, the odds of cure were increased by 1.045 
for every unit change in the percentage of total full nail length grown as healthy nail. So 
if a patient had a 10% increase, the likelihood of cure is increased by 1.04510 or 1.55. 
Table 9 
Odds Ratios at Each Trial Visit for Percent of Total Nail Grown as Healthy Nail 
Associated With the Complete Cure 
Week Crude 
OR 
Adj. OR* 95% CI % Change between Adj. 
and Crude ORs** 
4 1.048 1.045 1.024 1.066 0.29% 
8 1.056 1.059 1.041 1.077 0.28% 
12 1.076 1.074 1.056 1.092 0.19% 
16 1.066 1.063 1.048 1.077 0.28% 
24 1.060 1.058 1.046 1.070 0.19% 
36 1.071 1.068 1.055 1.081 0.28% 
* adjusted for age group, duration of current onychomycosis, percent of prescribed drug 
taken, sign of onycholysis on the target big toenail, history of antifungal treatment, sex, 
percent nail infected prior to start the treatment, length of nail grown during the baseline 
period, KOH microscopy result at corresponding visit, and mycological culture result at 
corresponding visit. 
** % change=(|cOR-aOR|/aOR) × 100. 
 
Since the largest adjusted OR (1.074) was seen at Week 12, results of the full 
model at Week 12 are presented in Table 10. The results from the final model after 
dropping variables with a p-value >0.1 are presented in Table 11. Both models fitted the 
data well. The p-values from Hosmer and Lemeshow goodness-of-fit test for both models 
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were 0.8864 and 0.4589, respectively. Two models showed that a complete cure was 
significantly associated with younger age group, first time treated with an antifungal 
agent, and a smaller area of infection. Sex was also significantly associated with the cure. 
Female patients were more likely to be cured than male patients (OR = 1.60, 95% CI 
1.033–2.474 from Table 10). There was no significant interaction between each of these 





Odds Ratio and 95% Confidence Interval of Potential Risk Factors at Week 12 in 
Association With Achievement of the Complete Cure From the Full Logistic Model 
Factors OR 95% CI p-value 
Age < 40 vs. > 65  2.902 1.278 6.591 0.0109 
Age 40–65 vs. > 65 2.028 0.950 4.332 0.0678 
Duration of current Onychomycosis 
(months) 
0.999 0.997 1.001 0.3166 
Percent of prescribed drug taken 1.018 0.968 1.069 0.4923 
Sign of onycholysis (no vs. yes) 1.128 0.638 1.995 0.6778 
History of antifungal treatment (no vs. yes) 1.841 1.091 3.104 0.0221 
Sex (female vs. male) 1.599 1.033 2.474 0.0350 
Percent nail infected prior to start the 
treatment 
0.991 0.982 0.999 0.0355 
Length of nail grown during the baseline 
period (mm) 
1.127 0.924 1.374 0.2385 
KOH at Week 12 (negative vs. positive) 0.586 0.252 1.367 0.2165 
Culture at Week 12 (negative vs. positive) 1.439 0.932 2.220 0.1002 
Change in % of total nail grown as healthy 
nail at Week 12 since baseline (%) 





Odds Ratio and 95% Confidence Interval of Risk Factors at Week 12 in Association With 
Achievement of the Complete Cure From the Final Logistic Model 
Factors  OR 95% CI  p-value 
Age < 40 vs. > 65  3.237 1.474 7.108 0.0034 
Age 40–65 vs. >65 2.160 1.027 4.547 0.0425 
Sex (female vs. male) 1.618 1.056 2.477 0.0270 
History of antifungal treatment (no vs. yes) 1.808 1.081 3.024 0.0241 
Percent nail infected prior to start the treatment 0.990 0.981 0.999 0.0227 
Change in % of total full nail length regrown as 
healthy  
1.073 1.056 1.091 <0.0001 
 
Similar to the results seen in testing Hypothesis 1, the negative culture result was 
significantly associated with a complete cure at Week 16 (OR = 1.969, 95% CI: 1.232–
3.147), and at Week 24 (OR = 3.367, 95% CI: 1.738–6.525). Then it was no longer 
statistically significant at Week 36 (OR = 2.089, 95% CI: 0.834–5.235). A negative 
microscopy result was only significantly associated with a complete cure at Week 36 
with OR = 2.870 (95% CI = 1.647–5.002).  
Hypothesis 1 and Hypothesis 2 showed the similar results in assessing the 
relationship between the healthy nail growth and achievement of complete cure. The 
logistic regression models produced a similar set of risk factors. The ORs in Hypothesis 2 
were smaller than those in Hypothesis 1, but this might be the result of the smaller 
measuring unit used in Hypothesis 2 (1 %) than in Hypothesis 1 (1mm). Both predictors 
could be used for the evaluation of complete cure in future studies. However, the length 
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in millimeters may be more intuitive for users than percentage. The former is also easier 
to measure. 
The next chapter presents the summary of findings, its implications for public 
health, and recommendation for actions. It also covers the experience with data gathering 




SUMMARY, CONCLUSION, AND RECOMMENDATIONS 
The success of antifungal treatment for onychomycosis is evaluated with a 
dichotomous variable of complete cure. Complete cure is defined as regrowth of a 
completely healthy big toenail and negative mycological results for both KOH and 
culture approximately 36 weeks after a standard 12-week daily oral dose of terbinafine 
treatment had stopped. The long gap between the final outcome and treatment cessation is 
the result of slow anatomical growth of the big toenail due to the fact that it normally 
takes 12 to 18 months to completely replace a big toenail. Current systemic antifungal 
treatments only achieve a complete cure rate of 20-50% (Baran & Kaoukhov, 2005; de 
Berker, 2004). Because of the long wait time for treatment outcome, various approaches 
have been proposed to improve the rate of complete cure and ensure a better outcome 
(Baran & Kaoukhov; Gupta & Ryder, 2003; Gupta & Tu, 2006). However, these 
approaches have been based on empirical evidence. The rate of healthy nail growth is 
considered an important predictor for the successful outcome of antifungal drugs for 
onychomycosis; however, there is little evidence to support this assertion. This 
population-based study may be the first to provide a statistically significant positive link 
between these two variables. 
This study shows that healthy nails among patients who have achieved complete 
cures with a full-course of terbinafine treatment grow faster and at a more constant rate 
during the 48-week trial period than patients who have failed from the same treatment. 
This is true when growth is measured by the nail length or when growth is measured as a 
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percentage of the total full nail length. The difference in the healthy nail growth becomes 
statistically significant as early as Week 4. At this point in time, the mean change in the 
healthy nail length among cured patients is nearly double of that seen among failed 
patients (1.23 mm vs. 0.64 mm). At the completion of 12-weeks treatment with 
terbinafine oral tablets, the average length of healthy nails among cured patients is 3.6 
mm while the average length of healthy nails among patients who failed treatment is only 
1.9 mm. 
Speed and consistency of healthy nail growth play important roles in the 
achievement of a complete cure as shown in Figure 3 and Figure 4. Regardless of the 
final treatment outcome, toenails generally grow faster while on treatment than 
posttreatment. Patients whose healthy nails grow at a faster and steadier speed are more 
likely to achieve a complete cure during the 48-week period. 
Nail growth is still significantly associated with the achievement of a complete 
cure at each scheduled visit after controlling for significant factors such as age, gender, 
disease severity, nail size, and antifungal treatment history. Adjusted odds ratios range 
from 1.349 to 1.630 throughout the trial period when the healthy nail is measured in 
millimeters. Adjusted odds ratios are between 1.045 and 1.074 throughout the trial period 
when healthy nail growth is measured as a percentage of the total full nail length. For 
both measurements, adjusted OR is the highest at Week 12 and the lowest at Week 4. The 
same magnitudes of risk are presented from the final model by dropping variables with a 
p-value greater than 0.05.  
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Mycological microscopy and culture results are integral parts of achieving a 
complete cure. However, the significance of their associations with a complete cure 
comes at a later time than the pattern of clear nail growth. Furthermore, the culture results 
are associated with a cure at a much earlier time than KOH test results. In testing 
Hypothesis 1, a negative culture result is significantly associated with a complete cure 
outcome at Week 16, while negative KOH microscopy results only become significantly 
associated with complete cure at Week 36. The result is logical because fungal hyphae 
will still be visible under a microscope even though the fungi have been killed and cannot 
be grown in the culture medium. This pattern of significance of the mycological results 
with the achievement of complete cure is similar to that found by Sigurgeirsson, Paul, et 
al (2002), in which authors also identified the earlier significance of culture results than 
KOH testing. 
Healthy nail growth also reflects the mycological results. Without killing fungi, 
the nail will not grow out healthily. To maintain continuous growth of healthy nail 
posttreatment and eventually achieve a complete cure, negative mycological results are 
absolutely required. Since healthy nail growth is linked to treatment outcome much 
earlier than a mycological culture or KOH test, it would be a more valuable indicator of 
treatment outcome. 
Healthy nails—as measured in actual length or in percentage of total nail—
produce a similar relationship with the achievement of complete cure. Logistic regression 
models produce a similar set of risk factors for both variables. Though ORs for the 
percentage (in Hypothesis 2) are smaller than those for length (in Hypothesis 1), this 
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might be the result of the small units used in Hypothesis 2 (1 %) as compared to those 
used in Hypothesis 1 (1 mm). Both variables can be used to monitor treatment response 
and predict final treatment outcome. In this manner, the selection of an indicator could be 
the user’s own preference. Use of the nail length indicator may be more intuitive than use 
of percentages; they are also easier to calculate.  
Besides nail growth and mycological results, other factors significantly associated 
with achievement of complete cure include patients of a younger age, treatment naïve 
patients (i.e., patients who have not received antifungal treatment for onychomycosis), 
less severe infection, and smaller nail size. Patients under the age of 40 are three times 
more likely to be cured than a 65-year-old patient. A patient between the ages of 40 and 
65 years old is also twice likely to be cured than a 65-year-old. Treatment naive patients 
have a double chance of cure than those who had received prior antifungal treatment. 
Female patients appear to have better response to the treatment than male patients. A 
smaller area of infection is also significantly linked to the cure rate, though the OR and 
its 95% CI are very close to 1. When nail growth is not measured by the percentage of the 
total full nail length, shorter nail size indicates a better chance of cure (OR = 0.81, 95% 
CI: 0.733–0.888).  
It has been demonstrated that terbinafine can speed nail growth (Geyer et al, 
2004). This study supports such findings because the toenail grows faster while on 
treatment than in the posttreatment period. This may relate to terbinafine concentration in 
the nail: A higher concentration results in faster nail growth. This may be an indication 
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that additional posttreatment therapy may speed nail growth and increase the rate of 
complete cure. 
Experience With Measuring Nail Length 
The length of healthy nail was measured from the proximal nail fold to the lowest 
point on the healthy-diseased border. The measurement was taken from the middle of the 
nail. Measurement of nail growth as analyzed from a photograph of the nail had been a 
challenging task. A good measurement of nail length required a proper camera angle, 
proper light exposure, clear markings, and well-defined nail shape. At times, the toenail 
surface grew at a concave angle downward. Therefore, some nails were twisted instead of 
being straight in the mid-nail area. So the correct measurement of actual nail length was 
nearly impossible to ascertain. The site of the infection also affected the measurement: 
Because the length of the lateral edge was normally shorter than the one mid-nail, a large 
change in clear nail length from one visit to another could be seen when only the lateral 
edge was diseased.  
It was definitely an advantage to have a complete set of nail photographs during 
the trial period for each patient as it allowed a chronological review of the changes in 
disease and nail growth over time. The lessons learned from this study could help 
physicians and researchers assess the nail better. Since marking the healthy-diseased 
border for this study was performed at each trial visit without comparison to previous 
photographs, these photographs revealed the tough challenges in disease assessment. 
There were some inconsistencies in marking the healthy-diseased border over time within 
a patient. Some markings changed dramatically from one visit to another, even though 
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the disease itself did not change much. There was also a difference between how 
individual investigators marked the healthy-diseased border; different investigators might 
make differing assessments of the appearance of the nail and one might consider the area 
healthy while another considered it diseased. Additionally, there was a tendency for 
investigators to be more critical in marking the healthy-diseased border when the nail 
became clear than when it was not clear. Since nails normally appeared much cleaner 
after treatment with terbinafine, the healthy area might become smaller than when nails 
were covered with diseased tissue. This might come as a result of it being easier to see 
the nail when it was clean than diseased. 
Reviewing each set of photographs showed that nails did not always grow out 
uniformly. The location of the lowest point of the healthy-diseased border changed from 
visit to visit. Therefore, it was not feasible to use one fixed point to monitor healthy nail 
growth.  
These study results represented nail growth in general. It should be remembered 
that there were some unique cases, as documented by the photographs. For example, 
some patients grew new nail at a much faster rate than others. For some cases, it was 
somewhat difficult to measure the total nail size at the beginning of treatment because 
nails had been destroyed or were misshapen. Closely clipped nails could affect the 
measurement as well, as some nails were clipped much shorter while others had nails that 
extended beyond the free edge of the nail bed. 
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Implications for Social Change 
Because of the relatively high prevalence of onychomycosis in the general 
population and the lack of optimal treatment, this study bears public health importance. 
Only when the disease is effectively managed can the spread of the disease be reduced. 
Improved treatment outcome will also minimize patients’ sufferings and avoid more 
severe consequences. 
This study has demonstrated a clear association between the growth of healthy 
toenails and achievement of a complete cure. This could set a foundation for a future 
treatment strategy for the disease and affect future research of antifungal agents. These 
positive results may help physicians to better monitor the progression of healthy nail 
growth during both the treatment and posttreatment periods. Physicians may track the 
nail growth over time and predict the treatment outcome in comparison with the results 
presented here, resulting in better treatment of the disease since it could help them to 
decide if and when booster treatment is necessary. It will be useful to take nail 
photographs regularly and compare the current photo with previous ones when assessing 
a treatment response.  
For pharmaceutical researchers, these results may help them to better selection of 
future antifungal treatment. For example, instead of conducting a full scale and large 
sampled clinical trial at the early development phase, they could shorten the trial duration 
to 12 or 16 weeks and use nail growth rate as a surrogate marker for treatment success. 
This can also be used to develop combination therapy by testing when to add a second 
agent. By reducing the cost of research and development, the prices of newer antifungal 
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agents could be reduced. This will be good news for both individual patients and the 
entire healthcare system.  
Of course, the findings would need to be confirmed by future studies because this 
may well be the first study to reveal such a relationship.  
Recommendations for Action 
Antifungal treatment is required to eradicate fungi from the nail because there is 
rarely a spontaneous cure for onychomycosis. The positive findings from this study 
should be shared with physicians, patients, and pharmaceutical researchers.  
First, this could be done through publication and scientific conferences so results 
would be made public to target audiences. Second, a growth chart is recommended for 
each patient to monitor nail growth.  
Area for Further Studies 
Since this is the first time a positive link between the healthy nail growth and 
achievement of complete cure has been demonstrated in a population-based study, these 
results should be confirmed by additional studies. Some background noise or risk factors 
apparent in other studies were not entirely controlled in the current study, so future 
studies may be designed to include a placebo arm as well as assessment of important 
clinical features such as matrix infection and nail thickness. Future studies may also have 




Nail growth patterns and relapse rates may need to be examined more closely. It 
will be important to understand what the risk factors are and how the nail would 
subsequently show signs of relapse so preventive procedures could be implemented.  
Additional studies could be performed to evaluate if booster treatment can 
improve efficacy. Such studies need to explore the type of boosters to use, time to start, 
and duration of treatment.   
Conclusion 
The healthy nail growth measured in length (mm) or in percent of total full nail 
length is significantly associated with the achievement of a complete cure. The 
significance could be observed after 4 weeks of terbinafine treatment. With every 
millimeter increase in healthy nail length, the chance of cure could increase by 1.35 
times. Week 12 seems to be the best time to assess the treatment outcome because 
healthy nail length and percent of total nail grown as healthy at this visit had the largest 
odds ratios, 1.63 and 1.07, respectively. Also the mean healthy nail length at Week 12 in 
cured patients is much longer than that seen in failed patients (3.56 mm vs. 1.90 mm). 
Speed and consistency of healthy nail growth are important to achieve a cure. Significant 
baseline factors for cure are younger in age, are treatment naïve, and having less severe 
disease. Healthy nail growth appears to be a better predictor than negative mycological 
results because significance of negative mycological culture results started at Week 16 
and negative KOH microscopy results started at Week 36. Booster treatment may 
increase the chance of cure because healthy nails grow faster when terbinafine 
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concentration in the nail is higher. Further studies may be required to assess the effects of 
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